gsk corporate responsibility report ceochairman statement employment practices global leadership survey diversity employee development internal communication health safety human rights employees suppliers access medicines developing world developed world leadership advocacy hivaids accelerating access initiative patient advocacy gsks unique business model vaccines science policy conferences importation medicines community investment value community investment humanitarian relief major public health initiatives community partnerships supporting education employee involvement engagement stakeholders engagement corporate responsibility engagement investors standards ethical conduct code conduct management certification business ethics training awareness monitoring research innovation animal research conduct clinical trials training auditing clinical trials public disclosure trial results products customers marketing codes practices marketing training compliance xedni wwwgskcom glaxosmithkline corporate responsibility report caring environment ehs management energy climate impact water waste ozone depletion volatile organic compounds product stewardship suppliers compliance verification statement progress towards targets managing cr summary indicators report pages report printed online gsk corporate responsibility report published th march wwwgskcom option print report provided convenience readers prefer hard copy report intended substitute full online report links information links shown underlined blue font throughout printed report brand names appearing italics throughout report trademarks either owned andor licensed glaxosmithkline associated companies exception viramune trademark boehringer ingelheim wwwgskcom glaxosmithkline corporate responsibility report ceochairman statement wwwgskcom glaxosmithkline corporate responsibility report products gsk delivers clear benefits patients around world great products however whole story society expects companies act responsibly pursuit success anything fact business human health makes even important operate highest standards corporate responsibility job selected people gsk defines way business ten corporate responsibility principles set standard everyone since responsible business reality practised employees times report show progress principle reporting significant achievements gsk one leading pharmaceutical companies essential area improving access medicines developing world example year tripled shipments preferentiallypriced combivir tablets help alleviate hivaids developing world went africa also granted five voluntary licences african companies produce hiv treatments locally proud commitment communities around world total community investment million million includes donation million tablets support elimination lymphatic filariasis debilitating disease threatens one billion people developing world responsible business practices also key good reputation pharmaceutical industry gsk continued come public scrutiny medicines developed tested marketed meet challenge must act integrity open approach important issues took important step year launch clinical trial register providing public access product information also want make information corporate responsibility performance widely available transition report internet integration environmental health safety information means information accessible stakeholders invite read report information corporate responsibility principles welcome comments suggestions sir christopher gent dr jp garnier chairman chief executive wwwgskcom glaxosmithkline corporate responsibility report employment practices wwwgskcom glaxosmithkline corporate responsibility report employment practices gsk leadership diversity employee internal health survey development communication safety employment employment practices corporate responsibility principle treat employees respect dignity encourage diversity ensure fair treatment phases employment provide safe healthy working environment support employees perform full potential take responsibility performance reputation business learn employment practices visit website gsk employs people countries success business depends us getting best people creating positive working environment offering competitive reward packages emphasise performance providing opportunities training advancement listening responding employees feedback expect employees meet high standards way carry work gsk gsk spirit defines culture principles expect employees work performance integrity entrepreneurial spirit focus innovation sense urgency passion achievement regular performance appraisals assess whether employees upheld principles requirements code conduct work results affect bonuses career progression see standards ethical conduct website information code conduct section explains approach performance covers results global leadership survey assessing employee satisfaction development gsks culture programmes recruit retain diverse workforce employee development performance appraisals communicate employees get feedback health safety wellbeing programmes wwwgskcom glaxosmithkline corporate responsibility report case study improving ergonomics barnard castle site new isolator one ergonomic improvement projects barnard castle taken several initiatives reduce ergonomic risks barnard castle site northern england site first place safety internal environment health safety awards excellence ergonomic improvement team eit formed site combat increasing lost time illnesses injuries related musculoskeletal disorders repetitive strain injury includes employees range different departments across site ergonomics considered design new equipment conduct risk assessments discomfort surveys consult trained local ergonomic experts encourage employees aware ergonomics seen increase ergonomic hazards reported eit produced two ergonomics manuals employees awareness training package completed improvement projects three year period including ones described warehouse employees operating narrow aisle vna hiracker trucks complained sore backs wrists trucks ten years old decided buy new fleet total cost primarily improve operator comfort trucks better controls require less effort manoeuvre headroom allow drivers sit stand comfortably fully adjustable seats designed provide good back support also efficient use less energy operate consulted employees purchasing installing new isolator used biological testing products order identify minimise ergonomic risks responding comments modified design isolator minimise amount bending twisting stretching necessary operate site achieved best ever ehs performance million hours worked without lost time injury illness model developed barnard castle rolled across gsk sites wwwgskcom glaxosmithkline corporate responsibility report employment global leadership survey sustainability success business rests significantly intangibles quality leadership culture ability develop talented people regular employee surveys help us monitor evolution gsks culture overall employee satisfaction company results used assess effectiveness people management practices identify areas improvement conducted second global leadership survey gsk managers survey completed managers countries gsk operates response rate tracked views first survey findings global companies ibm microsoft key survey findings responses generally positive significant improvement number positive responses core questions overall responses average points higher two years ago areas received high scores included business ethics managers reporting understand gsk code conduct applies job responsibilities pride company clarity role aligned gsks wider strategy mission example people department show commitment performance integrity see clear link work companys objectives people work cooperate get job done proud part gsk strategies department support pursuit gsk mission people department committed enabled make meaningful contributions feel encouraged come new better ways things report unethical practices without fear reprisal would gladly refer good friend family member gsk employment survey also produced clear messages areas improvement quite managers expressed concerns workload also frustrations able best work areas received lower scores still showed improvement included wwwgskcom glaxosmithkline corporate responsibility report amount work expected right gsk company great people best work choices made manager usually places quality business objectives deadlines budget etc satisfied recognition receive good job sufficient effort made get opinions thinking people work leaders department act teachers coaches champions development receive ongoing feedback helps improve performance comparisons companies responses many survey questions compared given employees companies crosscompany database includes responses around three million employees countries gsk scored highly compared companies several areas include manager effectively communicates gsk goals objectives report unethical practices without fear reprisal authority make decisions improve quality work scored average areas including amount work expected right choices made manager usually places quality business objectives important understand context second finding business exceptionally high quality standards built every level analysis response employees indicated concern related hitting deadlines rather quality per se improvement plans survey findings reviewed gsks corporate executive team business units developing plans deliver improvements key areas example additional ethics training planned parts business scored lower gsk average business ethics questions business units looking ways improve effectiveness employee development coaching feedback systems wwwgskcom glaxosmithkline corporate responsibility report employment diversity learn diversity visit website gsk committed employing diverse workforce environment employees treated respect dignity diversity benefits business workforce diverse backgrounds cultures outlooks helps us understand needs different patients customers delivering genuine equality opportunity sure best people right jobs best work gsk range initiatives ensure meet diversity commitments also monitor report data gender diversity management grade worldwide ethnicity uk us activity performance disability review conducted comprehensive disability review uk make sure gsk meeting needs disabled employees visitors review covered accessibility uk locations gsk web intranet sites audit employment policies review consulted employee focus groups external organisations including royal national institute blind employers forum disability carried audits assess access sites offices identified physical changes needed improve access implemented also provided training front house employees know assist disabled visitors necessary internet site also assessed making improvements ensure compatible browsers used visuallyimpaired people job applications gsk must made internet particularly important site fully accessible help readily available disabled applicants also provided training employees working human resources make sure disabled candidates receive equal consideration recruitment processes gsk received uk governments two ticks accreditation commitment employing disabled people wwwgskcom glaxosmithkline corporate responsibility report gender diversity women management grades female male total ab bands c c c c total total number women management increased incrementally year however women remain represented senior grades continue focus ways ensuring women genuine equality opportunity gsk held first women science event uk may enabling female science graduates give feedback gsk could attract women scientists women science take place year plan hold similar event us ethnic diversity uk employees ethnic minorities ethnicity us employee population people colour ethnic minorities accounted uk employees us people colour made workforce wwwgskcom glaxosmithkline corporate responsibility report multicultural marketing diversity awards annual multicultural marketing diversity awards recognise staff found creative ways reach wider audience employees customers communities awards given several categories including one employee attraction development retention years winners included asian employee support group north carolina provides english second language classes career development coaching members employee mentoring summer internships encourage young women become scientists famili vaccines initiative india encourages mothers children vaccinated campaign delivered languages conveys messages take account religious cultural differences across india us seniorcare programme help elderly people cope diabetes respiratory problems employee networks employee networks us encompass programmes asian african american hispanic gay lesbian employees first gay lesbian network leaders conference held share practical strategies leading employee groups wwwgskcom glaxosmithkline corporate responsibility report employment employee development gsk invests training development enable employees perform best ability develop careers provide range jobrelated training help employees build skills jobs effectively addition appropriate leadership training available managers employees enrol training programmes mylearning intranet site uk us employees attended development programmes countries similar opportunities exist employees worldwide data currently collected takeup programme people attended leadership edge global programme senior managers attended leadershipgsk programme middle managers employees attended foundation programme new managers managementgsk programmes designed help managers improve performance staff increase insight differing work styles strengths motivation also inspirational leadership workshop launched build main concepts leadership edge focusing senior leadership role inspiring motivating people high performance meet business challenges workshop targeted executives senior leaders particularly significant influence large numbers staff regular performance appraisals reward strong performance well helping employees set objectives identify training need twothirds gsk employees receive annual performance appraisal performance development planning pdp programme pdp process includes assessment well employees implemented gsk spirit principles use define culture significant impact bonus payments potentially reducing zero employee found followed spirit also affect future career development wwwgskcom glaxosmithkline corporate responsibility report employment internal communication good internal communication important achieving business objectives well creating open inclusive work environment range communications channels keep employees uptodate company news enable give feedback include mygsk global intranet site provides news updates qa section employees put questions directly ceo senior executives questions answered month behind news section gsk intranet gives companys position important issues linked press stories gsk spirit internal magazine reaches around employees throughout company four times year spirit gold award best internal magazine year communicators business awards europes biggest prestigious awards programme corporate communications townhall sessions employees levels company hosted senior management including ceo employees opportunity discuss progress business raise questions give feedback events employee surveys carried regularly throughout organisation enable staff give feedback global survey managers carried every two years see global leadership survey leadership conference senior managers celebrated employee contributions gsks future vision success role leaders play company following conference delegates debriefed teams messages outcome conference managers attended felt worthwhile use time many sites offices produce local newsletters help keep employees uptodate local company news confidential feedback mechanisms enable employees raise concerns include integrity helpline see standards ethical conduct europe works councils european employee consultation forum provide regular opportunities employees company management discuss issues see human rights website information also keep employees informed corporate responsibility programmes senior employees receive copy cr overview overview also included spirit internal magazine reaches around employees wwwgskcom glaxosmithkline corporate responsibility report track effectiveness communications questionnaires employee surveys leadership survey found respondents believe communications open honest objective feel access information need ambassador gsk see global leadership survey website details monitor questions employees put senior managers qa pages mygsk ensure pick potential areas concern also track readership news stories mygsk help improve relevance interest content wwwgskcom glaxosmithkline corporate responsibility report employment health safety manage health safety injury illness rates causes injury illness serious incidents fatalities health programmes safety programmes suppliers health safety employees contractors absolute priority gsk systematically assess risks associated operations take action protect employees others workplace track number cases workrelated injury illness resulting time work target reduce workrelated lost time injuries illnesses per hours worked every year end injury illness rate remained almost constant therefore meet target may partially explained improvements reporting systems including training resulting accurate data redouble efforts resume positive trend established led reduction illness injury rate routinely monitor causes incidents assess learned avoid happening health safety section report th year reported health safety performance legacy companies glaxo wellcome smithkline beecham individually published ehs reports number years prior formation gsk copies reports available corporate register website previous years published separate ehs report alongside corporate responsibility report year fully integrated two also details corporate responsibility reporting section report scope data health safety data covers calendar year collected pharmaceutical consumer manufacturing sites biologicals manufacturing sites rd sites well distribution centres major office locations smaller offices wwwgskcom glaxosmithkline corporate responsibility report sales locations include data sites operation part year notes attached charts explain scope data collection process parameter detail verification environment health safety sections report externally verified erm environmental resources management web pages verification applies indicated symbol see erms verification statement document wwwgskcom glaxosmithkline corporate responsibility report health safety manage health safety manage health safety integrated environment health safety ehs management system system incorporates ehs employee health policies ehs vision global ehs standards ehs plan excellence sets strategy improving ehs performance see ehs management system section website corporate environment health safety cehs employee health management ehm teams help coordinate health safety programmes see ehs management organisation section website pages summarise activities relate specifically health safety see ehs management website section corporate responsibility report information manage environmental broader ehs issues health safety feedback ehs audits aim conduct ehs audits operational site least every four years carry frequent visits selected sites depending assessment risk issues raised previous audits sites audited including three key office locations average score audits identified several priority areas chemical risk assessment control managing resilience mental wellbeing ergonomic risk assessment control scope adequacy workplace risk assessments management systems approach auditing ehs programmes root cause analysis ehs incidents implementation permittowork programmes management contractors sites required develop plans address weaknesses opportunities improve identified audit auditors monitor sites progress implementing plans ehs audit process scoring system refined based experience feedback trialling ehs auditing software intranet site help auditors track progress aim fully functional version ready ohsas certification four sites achieved certification international health safety standard ohsas first time brings total number manufacturing sites certified pharmaceutical consumer wwwgskcom glaxosmithkline corporate responsibility report manufacturing sites one additional site certified utilities area certified sites china egypt france india mexico poland turkey uk see audits certification website information certification environmental management standard iso health safety week gsk runs annual health safety week every october coincide european health safety week information kits sent sites help develop ideas plan activities employees sites countries took part health safety week activities included sports days safe driving education ergonomics training awarenessraising healthy eating lifestyles family participation events wwwgskcom glaxosmithkline corporate responsibility report health safety injury illness rates main indicator use measure health safety lost time injury illness rate ie workrelated injuries illnesses result time work measures include lost calendar days injuries illnesses reportable injury illness without lost time lost time injuries illnesses lost time injuries illnesses workrelated incidents serious enough result one days away work lost time injuries lost time illnesses corresponding combined rate per hours worked sites countries lost time injuries illnesses year one site china lost time injuries illnesses three years addition two sites canada mexico achieved million hours worked without lost time injury illness one site puerto rico achieved million hours worked without lost time injury illness three sites bangladesh pakistan singapore achieved million hours worked without lost time injury illness three sites india saudi arabia us achieved million hours worked without lost time injury illness ten sites china india pakistan poland spain uk us achieved million hours worked without lost time injury illness see injury illness milestones website cases workrelated mental ill health excluded overall illness rate consistency reporting cases less robust occupational illnesses variations way illnesses defined local legislation affects reporting however working address inconsistencies aim include cases future date cases workrelated mental ill health lost time rate per hours worked wwwgskcom glaxosmithkline corporate responsibility report performance lost time injury illness rate injury illness lost time injury illness rate business rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial per hours worked track number cases workrelated injury illness resulting time work target reduce workrelated lost time injury illness per employees every year end injury illness rate remained almost constant therefore meet target may partially explained improvements reporting systems including training resulting accurate data wwwgskcom glaxosmithkline corporate responsibility report redouble efforts resume positive trend established led reduction illness injury rate need achieve improvement put us back track achieve target notes injury illness charts health safety data cover employees contract workers directly supervised gsk employees injury illness rates per hours worked lost time injuries illnesses workrelated injuries illnesses serious enough result one days away work lost calendar days calendar days employees could work workrelated injuries illnesses helps provide measure severity injuries illnesses reportable injuries illnesses without lost time reported incidents result time away work lost time serious first aid generally less serious lost time include cases mental ill health lost time illness rates variations way mental illhealth defined reported across sites working address wwwgskcom glaxosmithkline corporate responsibility report lost calendar days injuries illnesses also measure calendar days employees could work workrelated injuries illnesses helps provide measure severity injuries illnesses although always accurate reflection eg illnesses hearing loss sensitisation result permanent disability without resulting lost time excluding workrelated mental illness lost days due injury lost days due illness additional lost days due workrelated mental illness approximately illnesses resulted permanent disabilities noise induced hearing loss sensitisation chemicals musculoskeletal illnesses performance calendar days lost rate injury illness notes injury illness charts box wwwgskcom glaxosmithkline corporate responsibility report reportable injury illness without lost time also measure number reportable injuries illnesses result time away work lost days workrelated injuries illnesses serious first aid generally less serious lost time injuries without lost time illnesses without lost time also additional cases mental illness without lost time rate less one per hours worked performance reportable injury illness without lost time rate injury illness reportable injury illness without lost time rate business rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial per hours worked wwwgskcom glaxosmithkline corporate responsibility report notes injury illness charts box contractors working gsk sites directly supervised gsk employees report health safety data construction contractors contract companies eg providing catering landscaping services work gsk sites supervise direct staff data contract workers directly supervised gsk employees included data gsk employees lost time injuries illnesses rate per hours worked also calendar days lost rate per hours worked reportable injuries illnesses without lost time rate per hours worked data included verification erm rates higher gsk employees contract companies responsible supervising employees also providing safety training wwwgskcom glaxosmithkline corporate responsibility report health safety causes injuries illnesses lost time injuries illnesses slipstripsfalls motor vehicle accidents overexertionsstrains main causes injuries resulting lost time mental illness musculoskeletal illness primarily repetitive strain injury infections main causes illnesses resulting lost time two outbreaks infection caused food poisoning onsite catered events resulting cases food borne illnesses resulted lost time causes lost calendar days similar performance categories lost time injury categories lost time ilness contact sharps thermal chemical caught slipstrips onbetween falls striking struck motor vehicle overexertions accidents strains notes injury illness charts box wwwgskcom glaxosmithkline corporate responsibility report reportable injuries illnesses without lost time overexertionsstrains slipstripsfalls contact sharps main causes reportable injuries without lost time musculoskeletal illness main type reportable illness without lost time accounting total followed infection performance categories reportable categories lost time injury without lost time ilness without lost time animal insect thermal chemical overexertions caught strains onbetween striking struck motor slipstrips vehicle falls accidents contact sharps notes injury illness charts box wwwgskcom glaxosmithkline corporate responsibility report health safety serious incidents fatalities deeply regret two workrelated employee fatalities one workrelated third party fatality egypt gsk sales representative fell elevator shaft business trip united states gsk sales representative died traffic accident third party fatality brazil visitor travelling gsk car died traffic accident working reduce traffic accidents driver safety programme see safety programmes website health safety data covers driving accidents occur business travel report data commuting accidents vehicle owned operated gsk however took seriously commuting accident nigeria truck collided bus owned operated gsk carrying gsk employees work leading six employee fatalities also report serious incidents ie incidents result permanent disability including amputations reported regulatory authorities accidents machinery resulted four employees sites japan pakistan india us needing part finger amputated addition one employee site india hand amputated one employee us needed surgery suffered permanent disability canadian employee suffered severe hand injuries following serious car crash investigate circumstances fatalities serious incidents assess learned avoid similar injuries also issue global alerts posted intranet site communicate information could help prevent similar incidents sites wwwgskcom glaxosmithkline corporate responsibility report health safety health programmes gsk recognise good employee health contributes good business health employee health policy sits alongside ehs policy sets overall commitment protecting promoting health wellbeing employees employee health management department supports sites implementing policy globally held workshops india europe us health practitioners share information best practice see employee health management organisation website internal audits identified number weaknesses way sites manage key health risks including chemical agents ergonomics resilience mental wellbeing responded developing new strategies chemical exposure ergonomics resilience mental well introducing number new management tools resources plan set new employee health scorecard measure monitor effectiveness programmes processes promote health productivity employees aim improve gsks business performance enhancing health resilience people key health achievements resilience mental wellbeing cases mental illness without lost time gsk significant reduction also corresponding decrease number days lost workrelated mental illness mental illness leading cause workrelated sickness absence accounting workrelated lost time illnesses average gsk case workrelated mental illness resulted days work significantly average number days lost causes occupational illness causing lost time use term resilience describe set skills behaviours needed cope successfully pressures rapidly changing work environment strategies resilience mental wellbeing uk us plan develop groupwide strategy issues year total teams uk used team resilience toolkit developed identify manage risks measure performance wwwgskcom glaxosmithkline corporate responsibility report many countries including uk us continued put place health stressreduction programmes relevant local conditions cultures workplace risks many designed reduce workplace pressure encourage good worklife balance examples include personal team resilience personal skills time management flexible working options health awareness education initiatives healthy food choices onsite catering facilities also provide fitness facilities either onsite offsite many sites example uk fitness centre gsk house brentford almost half employees work members us fitness facilities nine sites average employees enrolled use facilities sites singapore uk received awards initiatives promote resilience manufacturing site jurong singapore received platinum award health promotion board singapore ministry health programmes encourage staff work hard play hard stay well bronze award also presented quality road site health programmes uk gsk resilience mental wellbeing strategy recognised uk health safety executive beacon excellence one best stress prevention strategies seen see approach resilience mental wellbeing website ergonomics cases musculoskeletal illness lost time mainly due repetitive strain injury accounted workrelated lost time illnesses second frequent category mental health also overexertionstrain injuries lost time accounting lost time injuries addition musculoskeletal illness related work leading cause sickness absence uk one highest categories healthcare spend us response challenges gsk developed ergonomics strategy created appointed new position fulltime professional ergonomist appointment end refine strategy programmes going forward approach managing ergonomic issues collaborative one involving employee health management staff safety professionals engineers line managers human resources functions sites carried office workstation risk assessments using online ergonomics risk assessment tool translated french italian polish portuguese spanish available intranet year also started work develop specific ergonomics risk assessment control tool nonoffice based employees piloted us extended globally wwwgskcom glaxosmithkline corporate responsibility report key part strategy beyond establish employeeled ergonomic improvement teams gsk sites uk teams thirteen sites sites achieved reduction musculoskeletal injuries illnesses examples ergonomics best practice developed shared intranet also created new area intranet people ergonomics responsibilities discuss issues share ideas access resources gsk ergonomics guidance updated reflect growing amount knowledge expertise field also plan incorporate ergonomic principles design tool kits new equipment processes manufacturing site barnard castle uk awarded st place safety category ehs excellence awards ergonomic improvements see case study website see approach ergonomics website occupational hygiene control chemical exposure cases respiratory dermal skin illness resulting lost time non lost time cases mainly due exposure chemicals together accounted workrelated illnesses developed strategy control chemical exposure sets plan action achieving goal shirt sleeve working environment ie workplace containment chemicals manufacture replaces need personal protective equipment year surveyed sites review way handle chemicals control exposure potent compounds exposure limit less micrograms per cubic metre note microgram one millionth gram helped us understand current position set priorities future introduced new tools help sites calculate cost different options controlling exposure chemicals resulted better understanding true costs control strategies frequently demonstrates engineering controls including containment systems cost effective traditional control methods extraction personal protective equipment number sites achieved significant savings installing new containment systems example parma italy new containment system toxic compound treating cancer led savings million dungarvan ireland new enzyme containment solution led financial savings million share best practice across sites made available intranet site engineering design kits controlling chemical exposures wwwgskcom glaxosmithkline corporate responsibility report solutions already existence know work preengineered solutions new designs also working develop new technologies make easier contain highly potent compounds continue refine way assess ehs hazards materials integrate research development process experts established new occupational exposure limits materials environmental limits based scientific data materials task force established antibiotic business improve control chemical exposures manufacture also addressing challenging task controlling exposure hazardous category compounds manufacture final formulation medicines go patients research new medicines testing material hazards may involve animal experiments gsk committed principle three rs reduce refine replace animal experiments see occupational chemical hazard evaluation animal testing website see approach occupational hygiene control chemical exposures website hivaids continued provide antiretroviral treatment arv gsk employees full parttime families developing world treatment provided adequately consistently local healthcare system see approach hiv website also developed number awarenessraising initiatives example factory nairobi kenya worked national aids trust uk develop hivaids educational materials funded positive action programme website provides support communities around world affected hivaids also offer preferentially priced arvs employers subsaharan africa provide care treatment staff see preferential pricing website wwwgskcom glaxosmithkline corporate responsibility report health safety safety programmes systematically assess risks anticipate potential accidents put programmes place minimise also learn investigating causes accidents make improvements accordingly introduced number new initiatives driver safety process safety driver safety driving accidents lost time accounted lost time injuries sales representatives drive long distances every year therefore particularly risk driving accidents global ehs standard occupational travel includes requirements driver safety developed technical instruction documents help gsk businesses comply standard cover wide range topics including driver training fitness drive vehicle selection risk assessment insurance accident reporting driver ergonomics driving environment monitor compliance standard internal audits self assessment questionnaires gsk also produced number tools help commercial fleet managers improve driver safety new driver safety programmes sales representatives introduced countries belgium bosnia brazil chile croatia czech republic france germany hungary ireland italy lithuania nigeria slovenia south africa spain sri lanka switzerland stringent requirements additional training added existing programmes number countries australia canada japan poland romania us uk comprehensive driver safety programme developed ready rollout three gsk commercial business units january continue expand driver safety programmes throughout commercial operations next years countries provide motorbikes scooters employees gsk motorbike rider safety manual produced distributed local languages employees countries motorbikes widely used including bangladesh india indonesia pakistan vietnam countries also fully implemented gsk requirement every driver motorbike wear helmet continue follow monitor implementation motorbike safety programme see approach driver safety ehs programmes gsk commercial website process safety safety engineering process safety programme ensures safety built manufacturing processes process hazard analysis pha must completed new project carried launched new wwwgskcom glaxosmithkline corporate responsibility report failure mode effects criticality analysis fmeca system help engineers develop safer processes see approach process safety safety engineering website developed safety data sheets sdss products available website see safety data sheets developed email notification tool automatically keeps employees uptodate changes sdss also started make environmental testing data available sdss also launched hazclass system help track hazardous material shipments worldwide ensure safe transportation materials per month see safe transport materials website wwwgskcom glaxosmithkline corporate responsibility report health safety suppliers supply chain complex ranges major strategic relationships contract manufacturers make final medicines us suppliers key materials ehs audits conduct regular ehs audits key suppliers check comply ehs standards key legislation carried sitebased ehs audits existing potential suppliers found wide variation performance across sites audited lowest score highest make recommendations sites following audits process monitor progress particular focus poorly performing sites three potential key suppliers achieved unacceptable ehs scores less therefore source existing supplier scored found health safety generally well managed supplier sites europe north america however identified challenges emerging economies especially areas relating fire prevention response occupational hygiene control chemical exposure identification hazards risks systems reporting investigating incidents see suppliers contractors environmental section website ehs audits supplier performance approximately centrally managed key suppliers include contract manufacturers suppliers materials working towards reporting health safety performance contract manufacturers difficult process collecting data sites contract manufacturers independently managed collected health safety data major contract manufacturers data included verification erm employees contract manufacturers reported health safety data worked total million hours manufacturing gsk products lost time injury illness lost time injuries lost time illnesses corresponding combined rate per hours worked wwwgskcom glaxosmithkline corporate responsibility report injury illness without lost time injuries without lost time illnesses without lost time corresponding combined rate per hours worked calendar days lost injury illness lost days injuries lost days illnesses corresponding combined rate per hours worked wwwgskcom glaxosmithkline corporate responsibility report human rights wwwgskcom glaxosmithkline corporate responsibility report human rights employees suppliers human rights human rights corporate responsibility principle committed upholding un universal declaration human rights oecd guidelines mnes core labour standards set international labour organisation expect standards suppliers contractors business partners working gsks behalf human rights broad subject relevant gsk number different contexts section discuss human rights gsk employees human rights issues supply chain direct employees generally highly educated skilled people striving make company attractive employer generally employment standards issues diversity equal opportunities provide adequate safeguards human rights supply chain complex diverse global recognise possible suppliers countries fully respect human rights workers community within sphere influence begun work ensure suppliers observe similar standards relations employees communities wwwgskcom glaxosmithkline corporate responsibility report human rights employees human rights employees work fully protected employment policies procedures details see employment practices website operate globally including countries government fully respect human rights believe presence countries vital ensure continued access medicines people aim create working environment employees standards match operations elsewhere ensure delivering commitment international human rights standards employment conduct annual global audit involves asking head human resources country operate report whether gsk employment practices meet standards following audit identified significant human rights issues workforce confirm gsk employ children anyone younger employees entitled join trade unions organise countries permitted national legislation committed listening responding views employees including works councils staff consultation committees discrimination harassment tolerated circumstances employees report concerns senior management confidential basis using global integrity helpline cases reported employees compliance function directly raised human rights issues wwwgskcom glaxosmithkline corporate responsibility report human rights suppliers supply chain complex includes highspend strategic relationships suppliers manufacture medicines us supply ingredients multiple gsk manufacturing plants also includes relatively low spend contracts locallysourced goods services cleaning products rubber gloves laundry services given size diversity global scope supply chain recognise possible suppliers countries fully respect human rights workers community within sphere influence begun work ensure suppliers observe similar standards relations employees communities first step incorporate clauses supplier contracts seek assurances suppliers commitment human rights includes compliance minimum wage legislation provision healthy safe work place free discrimination right employees join independent trade union opposition forms slavery exploitative child labour continued process begun include human rights clauses central contract templates use new suppliers working local procurement managers ensure incorporate appropriate clauses local contracts human rights clauses also introduced contracts existing suppliers renewed appropriate taking account varying risk human rights abuses different regions major existing suppliers asked confirm writing comply gsks human rights clauses began process contacting suppliers contacted suppliers second step audit monitor suppliers already conduct regular environment health safety audits contract manufacturers see suppliers contractors audits extended incorporate criteria questions human rights audits conducted human rights issues noted major suppliers compliance assessed regular supplier review meetings conducted gsks procurement professionals guidance document supplier compliance gsk human rights requirements developed employees working procurement explains standard contract clauses human rights importance supplier compliance standards monitor human rights issues ehs audits supplier reviews deal instances noncompliance part sourcing group management process provides training best practice programme gsk procurement wwwgskcom glaxosmithkline corporate responsibility report professionals human rights requirements included criteria used procurement selecting new suppliers supplier found met standards work agree improvement plans achieve compliance think better walking away problem however terminate contract supplier work towards compliance wwwgskcom glaxosmithkline corporate responsibility report access medicines wwwgskcom glaxosmithkline corporate responsibility report access medicines developing developed world world research preferential voluntary development pricing licensing partnerships eligibility noitforprofit pricing access access medicines corporate responsibility principle continue research develop medicines treat diseases developing world find sustainable ways improve access medicines disadvantaged people seek partnerships support activity access healthcare significant challenge many parts world millions poor people developed developing countries obtain medicines need section describes gsk helping improve access progress covers contribution developing world research notforprofit pricing partnerships voluntary licences preferential pricing arrangements discount cards middleincome countries patient assistance programs discount cards help uninsured patients us also support underserved communities worldwide donations funding practical support see community investment website wwwgskcom glaxosmithkline corporate responsibility report case study improving access medicine lithuania gsks new orange card lithuania giving senior citizens better access medicines need patients lithuania must contribute towards cost prescription medicines many senior citizens dont get treatment need afford pay cost private medical insurance cover expense doctors aware may sometimes prescribe based patients ability pay rather best option available general access innovative treatment limited lithuania standard living seniors relatively poor healthcare financing one lowest eu causes encouraged gsk lithuania implement orange card scheme launched successfully us orange card helps tackle problem giving senior citizens discount patients contribution gsk prescription medicines patients apply completing simple form eligible receive orange card post card launched july national advertising campaign promotional material sent pensioner organisations doctors pharmacies february patients applied orange card pharmacies registered participate target patients pharmacies joined programme july wwwgskcom glaxosmithkline corporate responsibility report access developing world healthcare crisis many parts developing world millions people access adequate food clean water governments resources fund clinics staff needed deliver healthcare aids pandemic made problems worse creating generation orphans depriving communities greatest asset fit healthy people tackling crisis complex challenge poverty fundamental cause huge barrier progress significant political extra funding needed new national international sources aid development build healthcare infrastructure believe responsibility governments intergovernmental agencies supplemented work many ngos work partnership deliver healthcare needed countries however pharmaceutical industry play significant role supporting work make important contribution investing research development targets diseases disproportionately affecting developing countries providing antiretrovirals arvs antimalarials vaccines specially reduced prices developing partnerships granting voluntary licences local manufacturers also support programmes improve health education community investment programme partnerships focus four major diseases lymphatic filariasis malaria hivaids diarrhoeal disease support given donations cash medicines well employee involvement see community investment website wwwgskcom glaxosmithkline corporate responsibility report access research development learn rd developing world visit website research development rd new drugs essential improve health developing world still effective treatments widespread lifethreatening diseases many existing treatments diseases malaria becoming less effective due drug resistance many diseases disproportionately affect developing countries means often viable commercial market new treatments new ways required encourage rd ensure new medicines vaccines reach people need one solution public private partnership ppp model encourages rd often accelerate products uptake developing world scale achieved company ppps involve companies public sector eg governments un bodies academia philanthropic foundations working together helping address lack effective markets companies provide technology development manufacturing distribution expertise public sector partners help fund rd delivery costs ensuring new medicines vaccines get people need gsk partner several ppps including medicines malaria venture mmv global alliance tb malaria vaccine initiative mvi ppps transforming landscape rd diseases developing world gsk created dedicated group pharmaceutical rd organisation based spain uk us focus diseases disproportionately affecting developing countries projects prioritised according social public health benefits rather commercial returns similar group exists vaccines organisation based belgium believe gsk currently company researching new vaccines treatments hivaids tb malaria world health organisations three priority diseases hivaids affects developed developing countries means commercial market new treatments encourages investment required rd gsk industry leader research hivaids treatment currently three major clinical development programmes progress different mode action total gsk clinical programmes medicines vaccines diseases particularly relevant developing world seven projects diseases disproportionately affect developing countries hivaids malaria leishmaniasis dengue fever tb hepatitis e n meningitis cervical cancer pneumonia wwwgskcom glaxosmithkline corporate responsibility report development pipeline end end diseases relevantto developing world pprree pphhaassee pphhaassee llll pphhaassee llllll mmaarrkkeetteedd ffooccuuss cclliinniiccaall aaccttiivviittyy hhiivv cidcid ccccrr aannttaaggoonniisstt rreettrroovviirr eeppiivviirr ccoommbbiivviirr zziiaaggeenn ttrriizziivviirr nnnnrrttii aaggeenneerraassee eeppzziiccoommkkiivveexxaa lleexxiivvaatteellzziirr pprrootteeaassee iinnhhiibbiittoorr vvaacccciinneess cidcid hhiivv nn mmeenniinnggiittiiddiiss ssttrreeppttoorriixxss rroottaarriixxrroottaavviirruuss ttbb mmaallaarriiaa ppnneeuummoonniiaaee hhaavvrriixxhheeppaattiittiiss aa ddeenngguuee ffeevveerr hheeppaattiittiiss ee ppaaeeddiiaattrriicc eennggeerriixxbbhheeppaattiittiiss bb cceerrvvaarriixxcceerrvviiccaall ttwwiinnrriixxhheeppaabb ccaanncceerr iinnffaannrriixxddiipptthheerriiaa tteettaannuuss aacceelllluullaarr ppeerrttuussssiiss ttrriittaannrriixxddiipptthheerriiaa tteettaannuuss wwhhoolleeccaallll ppeerrttuussssiiss ppoolliioo ssaabbiinnppoolliioo pprriioorriixxmmeeaasslleess mmuummppss aanndd rruubbeellllaa ttyypphheerriixxttyypphhooiidd hhiibbeerriixxhhaaeemmoopphhiilluussiinnfflluueennzzaaeettyyppee bb mmeenncceevvaaxxaaccwwmmeenniinnggiittiiss mmaallaarriiaa cidcid ppyyrriiddoonnee ccddaa ttaaffeennooqquuiinnee llaappddaapp hhaallffaann mmaallaarroonnee cchhlloorrpprroogguuaanniill ddaappssoonnee aarrtteessuunnaattee ttbb cidcid ootthheerr cidcid ssiittaammaaqquuiinnee zzeenntteellddeewwoorrmmiinngg aaggeenntt vviisscceerraall ppeennttoossttaammvviisscceerraall lleeiisshhmmaanniiaassiiss lleeiisshhmmaanniiaassiiss detailed information product pipeline foundin annual report link pyridoneproject enter phase progress malaria phase iib clinical trials malaria vaccine children showed unprecedented results data trials conducted malaria vaccine initiative mvi showed vaccine protected significant percentage children uncomplicated malaria malaria infection even severe forms disease least six months dr melinda moree director mvi commented findings represent breakthrough science malaria vaccines gsk working medicines malaria venture mmv world health organisation academic partners develop affordable fixeddose artemisinin combination treatment malaria africa based gsks lapdap received mmvs project year award pyridone project investigating new class compounds use malaria project chosen mmvs expert scientific advisory committee group experts malaria drug development rapid success identifying drug candidate since signed agreement mmv take lead compound clinical development wwwgskcom glaxosmithkline corporate responsibility report hivaids also made progress rd hivaids epzicomkivexa new fixed dose combination epivir ziagen approved us europe new onceaday combination tablet help simplify treatment regimens patients plan register across developing world received european certificate pharmaceutical product telzir new protease inhibitor approved europe registered developing world provide yet another treatment option september signed material transfer agreement international partnership microbicides ipm agreement gsks hiv drug candidates tested use microbicides prevent transmission hiv help women reduce vulnerability hiv infection sexual intercourse phase ii clinical trials ccr antagonist new class aids therapy produced positive data therapy tested clinical studies trials successful therapy may benefit people living hiv developed viral resistance existing hiv treatments proof concept trials drug interaction studies underway two additional hivaids compounds protease inhibitor pi non nucleoside reverse transcriptase inhibitor nnrti results expected reported gsk supporting clinical trials sponsored external organisations uks medical research council us national institutes health nih hivcollaborative research programme resourcepoor settings twenty trials currently underway mainly focussing public healthrelated issues involving patients developing world phase l clinical trials advanced hiv vaccine candidate continued major milestones report tb gsk corixa us pharmaceutical company began phase clinical trials new vaccine tuberculosis first study vaccine candidate conducted humans gsk continued screen compounds possible use new classes antitb drugs enzymatic targets mycobacterium tuberculosis tuberculosis whole cells search successful leads identified screening progressed candidates development wwwgskcom glaxosmithkline corporate responsibility report rotavirus rotavirus vaccine rotarix prevention gastroenteritis launched mexico january rotavirus infection leading cause severe diarrhoea vomiting gastroenteritis children two kills around children year one child every minute mostly developing countries rotarix tested largest phase iii clinical trial ever performed vaccine involving children seeking regulatory approval vaccine developing countries cervical cancer clinical trials cervical cancer vaccine cervarix produced positive results cervical cancer number one cause cancer deaths women developing world current studies suggest cervarix could reduce woman 's lifetime risk developing cervical cancer hope launch vaccine europe international region leishmaniasis gsk developing sitamaquine new oral treatment visceral leishmaniasis affects least half million people year developing world usually fatal untreated new treatment leishmaniasis urgently needed since current medicines either impractical becoming ineffective due drug resistance sitamaquine shown good efficacy phase ii studies clinical development ongoing wwwgskcom glaxosmithkline corporate responsibility report access preferential pricing learn preferential pricing visit website many barriers healthcare developing countries significantly poverty lack political led lack medical infrastructure hospitals clinics medical professionals prevents poor people accessing healthcare need affordability medicines also important two elements first ability governments patients pay medicines solving problem require developed country governments inter governmental agencies make significant additional financial resources available developing countries second element price medicines sold area gsk help address making key medicines available developing countries affordable prices sufficient quantities long required major commitment call preferential pricing aids malaria treatments available notforprofit prices public sector customers notforprofit organisations developing countries including countries covered us presidents emergency plan aids relief pepfarlink eligibility criteria guide prices sustainable make profit cover manufacturing distribution costs therefore sustain supply products long needed aim reduce notforprofit prices arvs antimalarial medicines whenever improvements manufacturing economies scale allow example combivir one key arvs available day compared april equates around per patient per year includes delivery costs compares favourably generic tablets february pricing report medecins sans frontieres shows average cost generic equivalents day lowest priced generic equivalent costs day addition negotiate public sector prices middleincome developing countries casebycase basis combine viable sustainable commercial return gsk increased affordability healthcare systems concerned gsk vaccines also available preferential prices work multinational organisations unicef world health organisation pan american health organisation governments non governmental organisations provide appropriate affordable vaccines developing world wwwgskcom glaxosmithkline corporate responsibility report progress shipped million preferentiallypriced combivir tablets developing world going africa nearly three times million tablets shipped routinely collect data preferentiallypriced medicines similar increase experienced epivir another arvs overall shipments still low given scale aids epidemic africa growth encouraging doctors hospitals clinics needed treat patients ensure better take preferentially priced medicines shipments preferentially priced combivir excluding diverted stock difficult estimate number patients treated result preferential pricing agreements since gsk control healthcare provision report unled accelerating access initiative aai suggests september patients developing countries receiving arv treatments supplied seven pharmaceutical companies aai includes patients africa increase since september gsks work aai see accelerating access initiative website end arrangements supply preferentiallypriced arvs countries includes agreements private employers added new supply agreements number middleincome countries include agreement chinese ministry health preferentially priced epivir tablets support chinas national hiv treatment programme number arrangements central eastern europe also introducing discount cards senior citizens several middle income countries see developed countries report wwwgskcom glaxosmithkline corporate responsibility report supply arrangements type customer employers public hospitals ngos govt non aai aai q q q q q q q q q q q q q q q q q product diversion notforprofit medicines illegally shipped back sale wealthier countries undermines ability provide notfor profit prices denies treatment intended patients poorer countries afford supply products low prices worlds poorest countries still make adequate return wealthier markets introduced different packaging tablet colours many notforprofit medicines help prevent product diversion special trilingual access packs approved combivir epivir trizivir countries receiving regulatory approvals red epivir combivir tablets gsk nine arvs registered eus antidiversion regulation company registered products regulation set five pilot projects collaboration ngos tanzania uganda nigeria zambia malawi assess impact extending preferential pricing wider range products initial results show lack healthcare capacity infrastructure major barriers capacity example number healthcare professionals funding improved increase take preferentiallypriced medicines example two pilot sites received funding us presidents emergency plan aids relief treatment opportunistic infections led increase orders antibiotics report findings pilots prepared end wwwgskcom glaxosmithkline corporate responsibility report access eligibility notforprofit prices notforprofit prices available countries includes least developed countries ldcs subsaharan africa ssa total countries addition private employers subsaharan africa provide care treatment uninsured staff purchase arvs notforprofit prices notforprofit prices also offered projects fully funded global fund countries covered us presidents emergency plan aids relief pepfar offer prices believe need greatest governments ngos agencies providing treatment notfor profit basis poorest worst affected countries also seek notfor profit arrangements individual countries facilitate access core public employees teachers nurses police firefighters covered private health insurance schemes negotiate prices private health sector casebycase basis depend revenues sales private market maintain local presence muchneeded infrastructure developing countries without local capacity would unable provide essential services training healthcare workers use products product support safety monitoring registration launch new products wwwgskcom glaxosmithkline corporate responsibility report access voluntary licensing partnerships learn voluntary licensing website learn partnerships website want play active role addressing healthcare crisis developing countries believe preferential pricing arrangements best way able ensure delivery safe quality product affordable price long needed focus efforts situations partnerships voluntary licences may also help increase supply medicines voluntary licences voluntary licences vl enable local manufacturers produce sell generic versions products gsk granted six vls antiretrovirals arvs africa hivaids devastating impact creative response unique situation decision grant vl depends number factors including severity hivaids epidemic country local healthcare provision economic manufacturing environment vls universal solution hivaids specific response particular set circumstances discuss vls potential partners casebycase basis selecting appropriate licensees key need sure manufacturer able provide longterm supply goodquality medicines implement safeguards prevent diversion medicines wealthier markets see preferential pricing website seek prevent voluntary licence holders combining active ingredients licensed us licensed active ingredients produce fixed dose combinations also use us food drug administrations fast track approval process arvs accelerate availability generic arvs pepfar programmes africa much discussion use compulsory licences intellectual property rights taken away rights holders compulsory licenses one flexibilities world trade organisations trips agreement intellectual property used humanitarian purposes however widespread use compulsory licences undermine intellectual property framework counterproductive long term rd new treatments especially commercial markets exist hivaids depends protection intellectual property wwwgskcom glaxosmithkline corporate responsibility report progress gsk granted five vls four south africa one kenya granted total five vls south african generics companies sale antiretrovirals public private sector customers south africa three vls also include rights sell countries subsaharan africa granted similar vl cosmos kenyan pharmaceutical company manufacture sale kenya countries east africa partnerships hiv treatment complex often requiring patients take combination different tablets different times day increases risk patients missing dose taking medicine wrong time reduce effectiveness treatment july gsk boehringer ingelheim bi agreed assess development copackaging combivir viramune bis hiv treatment sometimes used conjunction gsk arvs use developing countries given complexities hiv treatment recognise need multiple treatment options support efforts simplify treatment regimens aspen pharmacare developing combined pack voluntary licences granted gsk bi lamivudine zidovudine combination containing lamivudine zidovudine wwwgskcom glaxosmithkline corporate responsibility report access developed world learn patient assistance programs website access medicines issue developing world even developed countries patients afford medicines need particular problem us many people health insurance gsk developed patient assistance programs discount cards us help patients without insurance also introducing discount cards several middleincome countries enable qualifying patients obtain prescription medicines discount price programmes us patient assistance programs provide prescription medicines lowincome uninsured patients free minimal cost gsk operates two patient assistance programs commitment access covers cancer treatments bridges access covers medicines outpatients patients registered one phone call patient advocate receive medicine local pharmacy mail order patients received gsk medicines worth million programs based wholesale acquisition cost wac medicines gsk first pharmaceutical company us offer card providing savings medicines lowincome senior citizens disabled people known orange card enables people buy gsk outpatient prescription medicines discount introduced orange card provides savings patients received prescriptions resulted wac savings million patients gsk six pharmaceutical companies established together rx card provides discounts prescription medicines lowincome senior citizens eligible medicare patients received gsk medicines programme saving million based wac january gsk nine pharmaceutical companies created new card improve access medicines uninsured americans seniors together rx access card provides savings medicines approximately million people around uninsured people us eligible enrol also offer discounts prescription medicines cards launched centers medicare medicaid services us government agency orange cards middle income countries introduced orange cards providing discounts certain gsk prescription medicines eligible patients bulgaria lithuania ukraine wwwgskcom glaxosmithkline corporate responsibility report nature discounts varies countries depending needs patient way healthcare system operates orange card ukraine gives asthma chronic obstructive pulmonary disease patients average discount gsks seretide asthma medicine asthma patients age suffer disabilities affected chernobyl nuclear disaster also eligible eligibility assessed patients doctor patients receive medicine participating pharmacies hotline number set help patients find nearest pharmacy far patients enrolled lithuania patients must pay towards costs medicines known patient copayment orange card gives senior citizens average discount patient copayment gsk prescription medicines february patients applied orange card pharmacies registered participate see improving access medicine lithuania case study gsk orange card also introduced bulgaria may low income patients chronic diseases asthma chronic obstructive pulmonary disease diabetes card holders receive average discount four gsk prescription medicines patients registered far wwwgskcom glaxosmithkline corporate responsibility report summary gsk discount programmes country number value gsk programme patients benefit patients us patient assistance million programmes free minimal received cost medicines lowincome prescriptions uninsured patients us orange card discounts low million income senior citizens received disabled people prescriptions us together rx discounts low million income senior citizens joint received industry programme prescriptions us together rx access na launched discounts lowincome uninsured patients joint industry programme bulgaria orange card discounts launched lowincome patients chronic enrolled diseases lithuania orange card discounts launched senior citizens enrolled ukraine orange card discounts launched asthma medicine patients enrolled wwwgskcom glaxosmithkline corporate responsibility report leadership advocacy wwwgskcom glaxosmithkline corporate responsibility report leadership advocacy gsks unique science importation hivaids patient business model policy conferences medicines vaccines accelerating advocacy access initiative leadership leadership advocacy corporate responsibility principle establish challenging standards corporate responsibility appropriate complexities specific needs business building external guidelines experience share best practice seek influence others remaining competitive order sustain business multinational company use influence resources address social issues bring people together around common cause areas take lead issues coordinated sustained action group stakeholders required gsk participates leads several partnerships section highlights five examples gives flavour wide range projects contribute examples featured throughout report corporate responsibility section website media room wwwgskcom glaxosmithkline corporate responsibility report leadership advocacy hivaids accelerating access initiative gsk founder member accelerating access initiative aai formed may public private partnership seven rd based companies five un organisations unaids wb unicef unfpa objectives aai accelerate sustained access increase use appropriate good quality interventions prevention treatment hivaids ensure care treatment reach significantly greater numbers people need new alliances involving committed governments private industry un development assistance agencies nongovernmental organisations people living hivaids data released january aai estimated number patients developing countries receiving arv treatments supplied pharmaceutical companies aai reached end september includes patients africa increase since september increase encouraging much needs done aai companies committed working together accelerate trends bring benefits hiv care treatment need continue work closely affected communities nongovernmental organisations medical community governments multilateral organisations improve existing initiatives identify new opportunities gsk held chairmanship aai coordinated process review initiative ensure effective possible fight hivaids developing countries wwwgskcom glaxosmithkline corporate responsibility report leadership advocacy patient advocacy patient advocacy groups provide members support information live disease represent patient views lobby issues affecting patients interests important stakeholder gsk engage part aim patientfocused company annual patient advocacy leadership summit pals one ways summit includes forum patient groups learn gsk tell us better support work range workshops attendees including sessions media training sharing best practice throughout summit attendees receive information gsk patient programmes orange card disease management programmes pals extended us include patient groups worldwide people attended countries attendees represented different advocacy organisations including dedicated mental health hivaids respiratory diseases epilepsy cancer bone joint diseases diabetes feedback event positive example attendees europe felt event either excellent good investment time also highlighted key priorities patients rd better information disease access best available treatment gsk dedicated global advocacy team contributes planning pals coordinates interaction patient groups developed code conduct guide work patient groups patient advocacy manual best practice employees work part companywide effort initiatives include focus patient rd see focus patient website information wwwgskcom glaxosmithkline corporate responsibility report leadership advocacy gsks unique business model vaccines gsks new rotavirus vaccine rotarix received first launch mexico january well mexico rotarix launched latin american countries soon asia pacific countries already submitted regulatory approval countries worldwide rotavirus infection leading cause severe diarrhoea vomiting gastroenteritis children two affects children world rarely fatal developed countries however developing countries around children die rotavirus year first time major pharmaceutical company focused clinical regulatory strategy vaccine first region world european union us launch part gsks unique strategy deliver vaccines first people greatest medical need gsk solid track record providing vaccines globally years constantly developing novel unique approaches ensure new vaccines get areas world need fast possible said jean stphenne president general manager gsk biologicals case rotarix focused clinical regulatory strategy first countries medical need rotavirus vaccine one highest world rotarix tested largest phase iii clinical trial ever performed vaccine involved children mostly latin america asia also us europe wwwgskcom glaxosmithkline corporate responsibility report leadership advocacy science policy conferences gsk rd sponsoring series annual science policy conferences uk issues relating conduct pharmaceutical biomedical research aim promote discussion dialogue key stakeholders including policy makers regulators pharmaceutical companies scientists doctors patient groups first conference took place organised conjunction department health national institute clinical excellence focused medicines evaluated regulators pharmaceutical companies patients stakeholders looked current system could improved address medical needs effectively highlighted potentially important role nhs source research data evaluating medicines clinical practice conference organised department health academy medical sciences looked issues influencing quality clinical research uk including regulatory framework funding mechanisms provision infrastructure importance adequate career development training provisions highlighted actions needed improve clinical research benefit patients example need increase patient involvement putting information clinical research public domain wwwgskcom glaxosmithkline corporate responsibility report leadership advocacy importation medicines price brand name prescription drugs often lower countries us reason people us started buy prescription drugs abroad often internet us food drug administration fda approved drugs foreign vendors offer sale americans warned illegal unsafe gsk consistently opposed practice increased safety risks patients view risks confirmed report department health human services hhs task force drug importation chaired surgeon general richard h carmona task force looked safety issues around illegal drug importation potential cost savings made practice made legal full report found online httpwwwhhsgovimporttaskforce according report drugs imported consumers come us wide range countries drugs typically approved fda may fail conform many aspects fdaapproved drugs available us specifically report found importation increases opportunities counterfeit substandard drugs enter dispersed us drug distribution system american consumers currently purchasing drugs overseas generally significant risk task force concluded would extraordinarily difficult ensure drugs imported individual consumers meet necessary standards safety certification noting fda sufficient resource ensure safety personally imported drugs report concludes realistic level resources could ensure personally imported drugs adequately inspected assure safety since visual inspection testing oversight personally imported prescription drugs feasible practical time task force report states number new anti counterfeiting technologies development universally adopted may provide assurance safety authenticity prescription medicines however noted widespread adoption authentication technologies theoretically able secure us drug supply daunting task could raise cost imported drugs thereby reducing expected savings importation report concludes cost carrying safety checks imported medicine profits going middlemen would large part offset potential savings differences prevailing prices based analysis actual data drug prices volumes task force found total savings drug buyers legalised commercial importation would one two percent total drug spending much less international price wwwgskcom glaxosmithkline corporate responsibility report comparisons might suggest savings going directly individuals would less one per cent total spending savings would likely go third party payers insurance companies hmos report findings confirmed view patients stick trusted methods saving money approved medicines savings cards legal safe gsk sensitive patients concerns costs lack prescription drug coverage uninsured us led industry establishing first prescription savings card orange card founding member together rx programme wwwgskcom glaxosmithkline corporate responsibility report community investment wwwgskcom glaxosmithkline corporate responsibility report community investment value humanitarian major public community supporting employee commu nity relief health initiatives partnerships education involvement investm ent community community investment corporate responsibility principle make positive contribution communities operate invest health education programmes partnerships aim bring sustainable improvements underserved people developed developing world section explains invest communities information support developing countries preferential pricing voluntary licensing see access medicines website learn community investment website gsk provides money medicines time equipment help improve health education underserved communities support public health initiatives local community projects around world donate medicines support disaster relief efforts impoverished communities total community investment valued million million equivalent pretax profits donations made corporate contribution committees group level individual gsk sites support local communities section provides information programmes supported covers breakdown charitable donations donations medicines humanitarian purposes major health initiatives developing countries tackle lymphatic filariasis lf hivaids malaria diarrhoearelated disease community partnerships local support provided corporate level gsk sites support science education us uk gsk employees involved community investment wwwgskcom glaxosmithkline corporate responsibility report received range awards community investment activities including gsk finalist committee encourage corporate philanthropy awards phase one winners world business awards organised un development program international chamber commerce international business leaders forum projects supporting millennium development goals disease prevention education award phase project pharmaceutical achievement awards runner business communitys european impact award work barretstown science across world one businesseducation partnerships received conference board canada international partnership networks global best european language awards wwwgskcom glaxosmithkline corporate responsibility report case study tackling poverty malaria west africa weve known years mosquitoes spread malaria parasite yet information causing quiet revolution west african villages credit education initiative freedom hunger aims break cycle poverty ill health providing financial services education poor women gsks african malaria partnership funding new malaria education programme part project burkina faso one poorest countries world benefiting poor women rural areas access small loans savings facilities financial services joining village credit association meet regularly make loan repayments learn issues basic business skills child nutrition family planning malaria prevention treatment recent addition estimated africa child dies malaria every seconds many people unaware malaria spread mosquitoes feeding night malaria education teaches women prevent infection using insecticidetreated bednets recognise early signs malaria kiswenside one woman benefited trades soap clothing credit association able save part weekly income purchase insecticidetreated bednet even though hot accept must sleep net feel great satisfaction little pride make positive changes life says malaria education module expected reach half million people six west african countries benin burkina faso ghana mali togo senegal wwwfreefromhungerorgmalariahtml wwwgskcom glaxosmithkline corporate responsibility report community value community investment gsk donations valued million million supported programmes countries equivalent pretax profits figure includes medicines worth million million donated lowincome patients us patient assistance programs million million humanitarian product donations underserved communities around world product donations valued wholesale acquisition cost wholesale list price including discounts standard pharmaceutical industry method valuing product donations total community investment also includes million million management costs million million cash grants gsk member uks percent club companies donate least pretax profits charitable causes gsk regularly one top companies uks guardian giving list lists ftse companies percentage pretax profits contributed charitable causes method giving total wwwgskcom glaxosmithkline corporate responsibility report breakdown cash giving total members uks london benchmarking group lbg committee encourage corporate philanthropy cecp us report donations line guidelines set cecp values medicines wholesale acquisition cost line pharmaceutical companies wwwgskcom glaxosmithkline corporate responsibility report community humanitarian relief link updated stories website gsk donates essential products antibiotics help humanitarian relief efforts disaster zones support basic healthcare provision impoverished communities donations made request governments major charitable organisations may manufactured specifically partners gsk works partnership relief charities experience delivering humanitarian aid including americares direct relief interchurch medical assistance map international project hope activity donated lifesaving medicines support relief efforts countries immediate supplies antibiotics basic medicines sent response devastating tsunami south east asia severe flooding bangladesh humanitarian crisis sudan hurricanes affected central america caribbean us donated million doses antibiotics vials vaccines prevent spread infectious diseases countries affected tsunami also committed million million support organisations working relief operations disaster area total value humanitarian product donations million million based wholesale acquisition cost amount supplied year varies according demand gsk member partnership quality medical donations pqmd alliance pharmaceutical companies humanitarian agencies works encourage donation timely delivery appropriate medicines people need gsk follows guidelines product donations continue product donation programme humanitarian relief though amount product made available varies year response variable demand availability product wwwgskcom glaxosmithkline corporate responsibility report community major public health initiatives learn major public health initiatives website gsk supports public health initiatives developing countries donations medicines financial practical support focus efforts tackle three major diseases lymphatic filariasis lf elephantiasis hivaids malaria well phase education programme reduce diarrhoearelated disease progress eliminating lymphatic filariasis lf learn eliminating lf website gsk founding partner global alliance eliminate lf httpwwwfilariasisorg lf disfiguring disease prevalent tropical countries one worlds leading causes permanent disability global alliance partnership pharmaceutical companies world health organisation ministries health ngos community organisations aiming totally eliminate lf committed provide many doses albendazole anti parasitic drug used prevent transmission lf needed treat one billion people risk countries donated million albendazole treatments worth million million valued wholesale prices countries demand countries lower anticipated due problems extending programmes new regions donated million albendazole treatments since million people benefited programme also gave million million grants support global alliance eliminate lf team dedicated gsk employees helps advocacy research community mobilisation education initiatives rate lf infection already dropped many participating countries example egypt began nationwide campaign eliminate lf since million people received treatment risk infection infection rates fallen dramatically period egyptian government evaluating impact programme decide whether continue preventative treatment campaign expanded manufacturing site cape town south africa produce albendazole tablets help us deliver enough wwwgskcom glaxosmithkline corporate responsibility report treatments support elimination efforts atrisk countries facility expected start producing albendazole africa positive action hivaids learn positive action website gsk provides hivaids medicines preferential prices developing countries see access medicines website also support communities affected hivaids positive action part community investment set positive action recognises involvement people affected hiv aids key element helping control hiv pandemic positive action supported programmes countries partnership community organisations impact hivaids exacerbated hivaidsrelated stigma discrimination major barrier people accessing healthcare positive action seeks strengthen responses promote access care treatment vulnerable communities affected hivaids one example grant enable people living hivaids community leaders attend th international aids conference bangkok thailand important opportunity community organisations share experiences ideas participate technical workshops build skills improve aids services home countries conferences provide platform community representatives voice needs home countries champion equitable rights access healthcare people living hivaids expanded positive action new countries latin america asia central eastern europe response growing rates hiv infection areas included seed funding establish aids action europe aae new paneuropean hiv organisation consortium help mobilise resources fight hiv support new awareness prevention campaigns particularly countries recently joined european union latin america extended positive action bolivia argentina peru building successful programmes latin american countries programmes provide atrisk communities accurate uptodate information hivaids healthcare rights also launched positive action work national aids trust uk kenya hivaids business council help businesses develop education awareness programmes prevent discrimination help support employees affected hivaids wwwgskcom glaxosmithkline corporate responsibility report gsks african malaria partnership learn gsks african malaria partnership website african malaria partnership supporting education behaviour change programmes eight african countries partnerships three non profit organisations freedom hunger amref african medical research foundation plan international gsk investing million african malaria partnership three years expected benefit two million people encouraging effective prevention prompt treatment particularly among children pregnant women one programmes supported partnership credit education programme provides small loans business health education poor women senegal added five west african countries already participating programme see tackling poverty malaria west africa website information intend continue support communitybased malaria education behaviour change programmes personal hygiene sanitation education phase learn phase every year two million people die diarrhoearelated disease mostly children developing countries deaths often easily prevented better handwashing sanitation phase education programme helping reduce diarrhoearelated disease encouraging school children wash hands gsk established phase invested million million programme phase run partnership amref plan international well ministries health education phase currently operates five countries kenya uganda zambia nicaragua peru reaching children extended families programme impressive results example studies show diarrhoea rates fallen following introduction phase schools kenyan community ongielo group committed threeyear funding extend programme uganda partnership ministry health amref gsk convened phase steering committee representatives countries partners involved identify new partners help expand programme new countries wwwgskcom glaxosmithkline corporate responsibility report community community partnerships learn community partnerships website support wide range health education initiatives communities operate donations made centrally gsk sites support local charities good causes examples many community partnerships supported four main regions europe barretstown ireland lenvol france residential camps seriously ill children fun develop self confidence gsk gave respectively support camps employees also give time barretstown lenvol gsk employees participating three new european programmes launched receiving grant three years change advance disease prevention programme promotes healthy eating exercise aimed slovakian children living urban housing estates programme spain provides healthcare homeless abandoned children multi coloured lives interactive education programme help children disabilities integrate russian society international gsk contributed integrated management childhood illnesses imci initiative ethiopia partnership unicef imci aims reduce childhood deaths preventable treatable conditions pneumonia diarrhoea malaria measles malnutrition helps families improve health children better nutrition healthcare vietnam gsk supporting ethnic midwives initiative funding funding used build training centre women vietnams ethnic minority groups become trained midwives people ethnic communities often live poor rural areas little access healthcare services new midwives play important role helping improve mother child health home towns uk gsk supports charitable organisations uk included support medical research undertaken charities breakthrough breast cancer cystic fibrosis trust debra ehlersdanlos support group motor neurone disease association wwwgskcom glaxosmithkline corporate responsibility report gsk grant two years support british lung foundations baby breathe easy programme fund pilot scheme run nine regions across uk supporting parents carers young babies children five dealing diagnosed undiagnosed recurring chest problems us gsk donating three years arthur ashe institute urban health institute provides health education low income neighbourhoods nontraditional venues including african american afrocaribbean churches barber shops beauty salons laundromats tattoo parlours provides information english spanish help promote early disease detection encourage people multiethnic communities adopt healthier lifestyles continued support childrens health funds referral management initiative rmi threeyear grant million million helping rmi expand seven us states helping highrisk homeless children receive specialist medical care need foundations gsk operate single charitable foundation community investment programmes number small countrybased foundations canada czech republic france italy romania spain north carolina us local foundations support wide range charities healthcare initiatives last six years gsk france foundation supported number programmes african countries cambodia improve hivaids prevention education training care people expected benefited gsk foundation canada focuses much support hospice care helping terminally ill patients families foundation also supporting community programmes africa including extension phase project uganda north carolina gsk foundation usa endowed selffunding organisation supports initiatives areas mathematics science health education north carolina foundation awarded grants totalling million million wwwgskcom glaxosmithkline corporate responsibility report community supporting education gsk supports education uk us particular emphasis developing scientific literacy encouraging next generation scientists programmes focused inspiring children take interest science improving science teaching science education uk gsk supporting inspire innovative scheme postdoctoral researchers research education scheme developed partnership imperial college london specialist schools trust million million donation four years inspire aims raise achievement placing postdoctoral researchers specialist science schools train teachers support science teaching also gave support science across world international education programme enables school children countries discuss science issues internet biobubble giant inflatable model human cell developed edinburgh international science festival sponsored gsk biobubble toured schools across uk two science shows helping young people learn biology fun environment gsk committed million million four years help build new darwin centre natural history museum london enable better display museums important collection education us three year grant gsk helping national board professional teaching standards increase number science teachers north carolina philadelphia areas science summer free librarybased science education programme philadelphia received grant th year science summer reached children support focused science education also provide general support help improve overall education standards example gsk gave grant philadelphia education fund middle grade matters campaign improve education children aged wwwgskcom glaxosmithkline corporate responsibility report community employee involvement gsk employees encouraged contribute local communities volunteers hundreds employees give time good causes days caring us support science education school children uk science engineering ambassador scheme us partnership educational discovery september employees six gsk sites germany gave time community projects part new orange day initiative volunteers gave practical support projects activities included constructing bowling course old peoples home painting rooms womens shelter helping local charity develop marketing pr plan uk us also make cash donations charities employees done voluntary work gsk investment volunteer excellence give programme gave charitable organisations usa employees partners volunteered least hours year uk making difference programme provided grants charities based employee involvement many countries also encourage employees donate money charity matching money give providing taxefficient ways make donation accordance local taxation guidelines usa gsk matched donations employees retirees value million million addition gsk gave million match donations gsk employees gsk united way campaign one spirit caring one spirit sharing wwwgskcom glaxosmithkline corporate responsibility report engagement stakeholders wwwgskcom glaxosmithkline corporate responsibility report engagement stakeholders engagement engagement corporate investors responsibility engagement engagement stakeholders corporate responsibility principle want understand concerns interest corporate responsibility issues engage range stakeholders communicate openly addressing cr issues ways aim meet needs different groups allowing us pursue legitimate business goals engaging different groups interest way gsk operates important part responsible business practice stakeholders include employees investors patients doctors governments ngos listening open views actions build trust address concerns much discussion takes place normal course business example scientists meet regularly academics researchers pharmaceutical companies part work access medicine programmes community investment collaborate closely ngos multilateral agencies governments community groups information available stakeholder consultation following sections access medicine animal research ehs management leadership advocacy suppliers website interact governments give views policy issues affecting gsk pharmaceutical industry engage governments directly membership trade organisations pharmaceutical research manufacturers america phrmaand association british pharmaceutical industry abpi size global reach give us access policy makers recognise need use responsibly benefit patients business information approach external relations available external affairs website also meet stakeholders specifically discuss corporate responsibility issues feedback informs approach managing reporting subjects wwwgskcom glaxosmithkline corporate responsibility report section focuses cr engagement covers activities including cr survey key stakeholders engagement socially responsible investment analysts case study investor briefing rd animal research one issues socially responsible investment analysts look evaluating pharmaceutical companies inclusion investment funds need confident robust justification animal use animal welfare high priority research gsk reduce replace refine use animals research welcome engagement issue keen explain approach april gsk held briefing sri analysts research facility harlow uk aim illustrate role animals research explain animal testing small important part overall drug development process demonstrate animal welfare standards analysts visited animal research laboratory harlow saw animals used research accommodation opportunity question laboratory staff also visited high throughput chemistry laboratories viewed new technology introduced reduce animal testing animal mri scanner feedback event positive usefully provide clear insight animals cared also provided depth information processes work behind drug discovery development said one sri analyst information approach animal research see research innovation website wwwgskcom glaxosmithkline corporate responsibility report engagement engagement corporate responsibility dialogue stakeholders allows us understand concerns ideas helps set strategic corporate responsibility agenda gsk commissioned survey opinion leaders europe uk us participants included academics cr organisations customers government agencies investors media multilateral agencies ngos survey sought views performance social ethical issues cr reporting environmental issues covered addressed separate stakeholder panel survey provided indepth qualitative feedback designed produce statistics responses gave us clear indication gsk perceived areas stakeholders consider important cr survey findings participants asked identify key cr priorities gsk four considered material gsk access medicines developing world marketing ethics clinical trials conducted transparency results access medicines developed countries access medicines access medicines developing countries seen single important issue gsk seen well area programmes preferential pricing research diseases developing world community investment generally rated highly issue access medicines developed countries growing concern many participants positive negative views gsks performance area generally participants felt pharmaceutical industry improve access poor developed world ethical issues number participants raised issues business practices publicity associated gsks antidepressant paxilseroxat increased concerns marketing practices conduct clinical trials disclosure results respondents would like see issues covered depth addressing animal research also raised important issue gsk stakeholders gave positive response performance reporting wwwgskcom glaxosmithkline corporate responsibility report issue interviewees liked level disclosure reasoning given see animal research website cr reporting participants asked comment cr report felt report covered material issues gsk positive gsks commitment annual cr reporting majority stakeholders thought gsks reporting would improved increasing number performance indicators providing information future plans key issues increasing transparency tackling controversial issues direct way many participants felt separate cr environment health safety ehs reports made harder assess overall performance several participants wanted see information impact access medicine programmes clearer information scale health problems programmes addressing emerging issues next years participants felt access medicines developing countries continue biggest issue gsk drug pricing developed countries come greater scrutiny ethical issues around clinical trials marketing rd also significant responding stakeholders stakeholder survey provided us useful feedback grateful opinion leaders views able respond feedback immediately example fully integrated ehs reporting corporate responsibility report report increased number performance indicators continue review add appropriate future reports though important remember cr issues amenable numerical indicators objectives believe existing programmes two highest priority areas access medicines ethics substantial appropriate improved access clinical trial results launch clinical trial register website sometimes receive feedback suggestions stakeholders disagree unable accommodate without damaging interests company shareholders possible explain reasons example need use animals research continue engage stakeholders particularly opinion leaders gauge success cr programmes wwwgskcom glaxosmithkline corporate responsibility report engagement engagement investors investors taking growing interest corporate responsibility performance companies measure long term sustainability business decide companies included socially responsible investment sri funds gsk provides information investors number ways meet regularly sri analysts discuss cr issues respond requests information meetings analysts discussed issues including access medicines animal rights supply chain sales marketing ethics clinical trials also held several events sri analysts meet discuss issues senior management cr day sri analysts london attended analysts senior gsk managers analysts visited research laboratories harlow viewed high throughput chemistry laboratory animal research laboratory viewed new technology introduced part commitment rs see investor briefing rd website sri mainstream investors visited barnard castle manufacturing site uk find quality control environmental initiatives investment research organisations collect performance information via questionnaires used rate gsks cr performance vet gsk inclusion cr indices gsk included ftsegood dow jones sustainability indices wwwgskcom glaxosmithkline corporate responsibility report standards ethical conduct wwwgskcom glaxosmithkline corporate responsibility report standards ethical conduct code management training monitoring conduct certification awareness compliance business ethics ethics standards ethical conduct corporate responsibility principle expect employees meet high ethical standards aspects business conducting activities honesty integrity adhering corporate responsibility principles complying applicable laws regulations gsk products important health people around world particularly important operate high ethical standards act responsibly comply law gsk fully committed ensuring business practices meet high standards employees behave ethically honestly clear comprehensive policies procedures backed training monitoring help us section explains approach performance covers code conduct management certification business ethics training awareness programmes monitoring compliance systems information ethical issues sales marketing covered products customers website wwwgskcom glaxosmithkline corporate responsibility report case study ethics training administrative staff business ethics responsibility everyone gsk senior managers july held ethics seminar administrative support staff gsk house london aim raise awareness employee guide business conduct show ethics relevant administrative assistants example handling budgets dealing suppliers checking correspondence seminar organised gsk house admin community presented senior vice president legal department session highlighted potential ethical concerns around gifts entertainment attended people variety situations discussed support staff might need recognise ethical dilemma act integrity example assistants deal post often first see letters reporting suspected misconduct need deal letters promptly forward right people treat confidentially similar ethics seminar planned us administrators wwwgskcom glaxosmithkline corporate responsibility report ethics code conduct download gsk employee guide business conduct website employee guide business conduct contains company policies set standards behaviour expect employees requires employees act integrity comply law avoid conflicts interest report violations unethical behaviour detailed guidance provided including reallife examples constitutes acceptable unacceptable behaviour gsk employees access guide via company intranet induction training familiarises new employees business conduct standards obtain support guidance wwwgskcom glaxosmithkline corporate responsibility report ethics management certification business ethics commitment code conduct reinforced annual management certification programme requires top managers certify comply statement certification documentation managed electronically followed ensure completion managers completed certification full certification statement reproduced certify understand gsk committed principle performance integrity particular ensuring activities comply applicable laws received copy access gsk code conduct polgsk gsk corporate policies corporate policy index httpcorp ethicsgskcomcorporatepolicyhtm read understand employee guide business conduct accessible httpcorpethicsgskcomemployeeguidehtm complied applicable laws regulations gsk corporate local policies procedures people supervision received copies access gsk code conduct gsk policies informed responsibilities put place appropriate measures ensure people supervision comply laws regulations gsk corporate local policies procedures working behalf gsk understand responsibility promptly report actual suspected violations law regulations gsk corporate local policies procedures reported actual potential compliance issues aware concerning legal requirements company policies exceptions list compliance issues reported previously wwwgskcom glaxosmithkline corporate responsibility report ethics training awareness training awareness programmes make sure employees understand codes policies comply law know standards behaviour required global induction course includes training code conduct ensures new employees understand importance ethical conduct day one know deal potential dilemmas know seek help provide additional training employees working areas particular concerns sales marketing research development website addition provide training workshops keep employees date changes reinforce key elements gsk policies progress training workshops held international region japan includes operations outside europe us covered range business ethics issues including conflicts interest competition law corporate governance gifts entertainment marketing practices record keeping reporting legal ethical concerns workshops presented employees examples ethical dilemmas could face work asked consider would respond guidance provided help people understand appropriate responses rd elearning module entitled performing integrity launched present approximately gsk employees enrolled course successfully completed end performing integrity encompasses training code conduct conflicts interest acceptance gifts entertainment gsk employees objectives plan develop deliver additional training ethics compliance particular developing training reinforces employee obligations employee guide business conduct risks associated noncompliance expect develop deliver training course staff corporate functions including finance hr communications wwwgskcom glaxosmithkline corporate responsibility report ethics monitoring monitor awareness ethical issues company policies integrity helplines reporting channels regular surveys part commitment continuous improvement benchmark compliance programme major companies industry peers government regulatory standards monitoring awareness ethical issues leadership survey included questions business ethics survey completed managers results encouraging respondents felt people department show commitment performance integrity said understood gsk code conduct applied jobs felt could report unethical practices without fear reprisal results help us identify areas need focus necessary direct ethics training business units scored lower average questions gsk corporate ethics compliance function gsk dedicated compliance function works gsk business units identify compliance issues address increased number fulltime compliance officers four eight compliance officers senior level managers direct access leadership teams gsk functions source expertise point contact anyone question ethics compliance gsk policies compliance officers also responsible defining training needs section organisation communicating latest news policies legislation affecting gsk reporting concerns employees encouraged seek help report concerns suspected cases misconduct line management compliance officer confidential integrity helplines offsite post office box helplines post office box promoted employee guide business conduct gsk intranet training corporate ethics compliance function promoted source information wwwgskcom glaxosmithkline corporate responsibility report advice well mechanism reporting concerns data suggest employees understand see useful source advice guidance contacts compliance functions employees seeking advice information remaining employees reporting suspected cases misconduct addressing misconduct corporate ethics compliance department ensures allegations suspected cases misconduct investigated committed taking firm steps stop misconduct disciplinary action including dismissal taken necessary data disciplinary actions traditionally collected held local human resources departments operational value company began collate information first time collected data major business units including pharmaceuticals manufacturing corporate consumer healthcare rd believe data reasonable reflection process identified ways improve categorisation disciplinary actions mechanics data collation improve quality data future reports disciplinary actions taken result investigations allegations misconduct included dismissals separations disciplinary actions included verbal written warnings cases financial penalties employees staying company received training increased monitoring wwwgskcom glaxosmithkline corporate responsibility report research innovation wwwgskcom glaxosmithkline corporate responsibility report research innovation animal conduct training public disclosure research clinical trials auditing clinical trial results trials research research innovation corporate responsibility principle undertaking research innovating may explore apply new technologies constructively engage stakeholders concerns may arise ensure products subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulations legal standards applicable research development products research development rd new medicines vaccines core business makes significant contribution society new drugs brought huge benefits health quality life millions people last years continued rd remains important ever still many serious debilitating life threatening illnesses effective treatments treatments could significantly improved invested billion billion rd nearly people work rd gsk many ethical concerns relating biomedical pharmaceutical research use new technologies objective reporting clinical trial results gsk committed highest ethical scientific standards rd work section explains approach animal research conduct clinical trials public disclosure clinical trial results information approach new technologies see ethical issues rd website wwwgskcom glaxosmithkline corporate responsibility report case study focus patient everything discovery research make difference patients motivates explains karen lackey director systems chemistry discovery research karen leads group research chemists uk us japan work beginning drug discovery pipeline identifying creating molecules potential become new treatments previous role organisation chemistry team involved discovering lapatinib molecule use breast cancer treatments tested clinical trials karen believes introduction centres excellence drug discovery cedd gsk important impact cedds bring together range experts particular disease area speed drug discovery process way gsk rd set helps us prioritise efforts ensure discover effective medicines cedds researchers access experts main therapeutic areas evaluate every molecule value patients help us identify ones impact jill eric wolford understand importance better jill diagnosed breast cancer underwent nine months intensive treatment including chemotherapy radiation stem cell transplants recovered back work associate director gsks global clinical operations north america husband eric also gsk employee keen talk experiences meeting rd managers leadership teams talk jills illness shaped attitudes life work part gsks focus patient initiative aims reinforce patient centred culture across rd employees opportunity hear patients diseases gsk treatments helped new medicines need one goals motivate employees reminding benefits bring patients work jill welcomes initiative father breast cancer survivor im sure carry breast cancer gene look kids think please someone find cure breast cancer every case report form person family network friends treat people diseases need remind whole time wwwgskcom glaxosmithkline corporate responsibility report research animal research learn animal research website animal research essential understand disease evaluate safety effectiveness new medicines given people regulations require new medicines tested animals tested humans safety reasons vaccines tested animals time new batch produced estimate animal research accounts around gsk research expenditure gsk animal research laboratories europe japan us research around total animal research conducted external contractors behalf animals used laboratories rodents rats mice guinea pigs rabbits remaining includes fish ferrets pigs dogs cats primates animals used research three rs animal research laboratories subject strict internal legal controls gsk committed rs reduction refinement replacement achieving highest standards animal welfare rs commit us reducing number animals used study refining studies minimise pain maximise information obtained animal replacing animal studies alternative methods wherever possible provide extensive training rs staff involved care use animals number initiatives increase awareness animal welfare example produce quarterly bulletins review recently published journal news items subjects ukbased rs committee made gsk scientists statisticians senior managers animal technicians veterinarians encourages rs culture wwwgskcom glaxosmithkline corporate responsibility report gsk seminars production promotion recommended practice guidelines scientific procedures animal welfare animal welfare awards encourage employees find alternatives animal research awards presented twice year gsks rd chairman recognise employees made outstanding advances implementing rs awards made refinement animal model discover new treatments brain damage caused strokes innovative use imaging systems minimise animal use accelerating drug development use computergenerated prediction models cell tissue cultures replace animal testing europe also give gsk laboratory animal welfare year external researchers laboratories developing new techniques implement rs prize year project promoted improvements husbandry housing laboratory animals approach impact despite significant increase rd activity since number animals used gsk broadly similar ten years ago change rd activity compared change number animals used gsk animals used rd activity recent gsk advances research techniques supporting rs animal welfare blood sampling techniques reduce number animals used number injections required per animal increase quality efficiency sample collection refined methods collecting dna transgenic mice reduce animal stress increase productivity wwwgskcom glaxosmithkline corporate responsibility report development better facilities refined procedures ferrets guinea pigs exchange knowledge gsk laboratories different countries regulation internal controls laboratories comply strict national laws guidelines codes conduct animal welfare regulators carry regular unannounced inspections sites check standards animal care gsk laboratories external laboratories conducting research behalf must also follow code practice animal research gsk sponsors animal research companies institutions require entities meet legal requirements conduct animal based research establish best ability best practice standards animal care use followed 'best practice ' defined combination currently known scientific literature published recommendations knowledge experts within outside gsk addition gsk expects external collaborators demonstrate application best practice regarding animal research accreditation association accreditation assessment laboratory animal care international one example demonstrated ensure appropriate use animals proposed animal tests must reviewed ethical review committee also obtain independent evaluation association assessment accreditation laboratory animal care aaalac international ten laboratories accredited aaalac including animal laboratories uk us laboratories belgium italy spain achieved accreditation communicating approach believe important explain need animal research open laboratories host visits schools colleges animal welfare organisations others also made visits uk us schools discuss issues around animal research regular discussions animal welfare organisations investors interested parties example year contributed work nuffield council bioethics developing relationship new uk national centre rs ncrs wwwgskcom glaxosmithkline corporate responsibility report research conduct clinical trials learn clinical trials website safety effectiveness new medicines must evaluated clinical trials approved marketing regulators give approval trials demonstrate product safe effective benefits outweigh risks potential side effects new product typically tested three stages clinical trials involve healthy individuals patients relevant disease projects clinical development traditionally clinical trials carried western europe us however becoming increasingly challenging enrol sufficient patients countries increasing number scale trials often utilising available investigators patients therefore clinical trial capabilities eastern europe latin america asia improved significantly recent years starting conduct trials regions also conduct number clinical trials least developed countries world evaluate medicines diseases disproportionately affect countries clinical trial safety participants future patients first priority trials wherever conducted carried according international standards good clinical practice applicable laws regulations trial protocols reviewed external regulatory agencies relevant countries required protocols considered relevant ethical review committees whose remits cover sites studies take place safety data routinely collected throughout development programmes reported regulators line applicable regulations well reviewed gsk ongoing basis safety signals gsk global safety board responsible approval pivotal protocols internal assessment issues related patient safety arise development programme good clinical practice standards clinical trials conducted according good clinical practice gcp guidelines developed international conference harmonisation ich guidelines provide internationally accepted ethical scientific quality standard designing conducting recording reporting trials cover issues selection training trial investigators gaining informed consent trial participants monitoring quality assurance trials must approved independent ethics committee ensure trial justified designed conducted according wwwgskcom glaxosmithkline corporate responsibility report appropriate ethical standards committees power reject stop clinical trial ethics committee typically composed lay people medical professionals scientists conduct audit activities ensure clinical trials conducted appropriate standards see training auditing clinical trials website clinical trials eastern europe latin america asia pharmaceutical industry starting perform trials regions eastern europe latin america parts asia several reasons clinical trial capabilities regions improved significantly recent years trials countries help speed research process ensure new medicines get patients quickly fewer patients enrolled trials countries easier quicker find patients participate patients often used fewer medicines compared western europe us makes good candidates clinical trial easier assess effect products tested cost also factor operating costs countries lower objective carry clinical trials eastern europe latin america parts asia concerns trials regions may carried high standards western europe us gsk clinical trials carried standards gcp everywhere world vital protect patients ensure gain regulatory approval new medicines clinical trials diseases developing world gsk seven products clinical development diseases disproportionately affect developing world rd developing world diseases see access medicines website clinical trials diseases developing world need carried countries disease prevalent include worlds leastdeveloped countries trials sponsor irrespective location conducted according standards applied developed countries leastdeveloped countries extra efforts may required ensure meet global standards example areas low literacy levels difficult obtain informed consent trial participants cases investigators work independent witnesses make sure trial properly explained participants understand involved information policy procedures area see clinical trials developing world website wwwgskcom glaxosmithkline corporate responsibility report research training auditing clinical trials provide training ensure clinical trials performed high ethical quality standards also audit conduct clinical trials ensure carried according good clinical practice gcp guidelines employees involved designing conducting monitoring gsk sponsored trials trained gcp training mandatory employees must completed required training starting changing jobs training activities related gcp training activity represents successful completion elearning module instructorled course related gcp one employees complementary workers keep detailed training records routinely requested regulatory authorities undertaking inspection assess competence employees undertaking clinical trials gsk internal audit department independent departments responsible conducting clinical studies conducts audits gsk systems processes involved conduct trials well auditing clinical research organisations investigators performing clinical research behalf audits conducted audits investigator sites conducting gsksponsored trials representing approximately investigator sites participating pivotal clinical trials audits internal gsk systems processes used managing clinical trials data audits clinical research organisations carrying clinical trials gsks behalf audits gsk country medical departments audits conducted response suspected irregularities audit results reported quarterly rd risk management compliance board annually gsk audit committee concerns issues identified audits fully investigated appropriate action taken breaches gcp reported appropriate regulatory agency audits resulted findings needed investigation investigators reported regulatory agencies inspections investigators clinical research organisations independent ethics committees iecsinstitutional review boards irbs sponsors clinical trails also carried regulatory authorities ensure safety trial participants quality data trials conducted according gcp inspections gsk investigators used gsk conduct clinical studies wwwgskcom glaxosmithkline corporate responsibility report research public disclosure trial results gsks clinical trial register website pharmaceutical industry legally required disclose relevant data clinical trials appropriate regulatory authorities seeking approval new product approval sponsors continuing obligation provide regulatory authorities updated safety information clinical trials ensures regulators accurately assess safety effectiveness new medicines monitor safety approval safety efficacy information provided doctors prescribing information approved regulators addition need use ways prescribing information appropriately communicate results clinical trials healthcare practitioners others use evaluate use medicines gsk taken significant step year respond concerns access trial results approach gsk follows phrma principles conduct clinical trials communication clinical trial results committed timely communication results products approved marketing wherever possible publish clinical trial results peerreviewed scientific medical journals conference abstracts proceedings used research healthcare communities obtain latest information treatments publications describing results gsks clinical trials number publications year depends number trials completed number accepted publication wwwgskcom glaxosmithkline corporate responsibility report number publications gsk clinical trials gsk guarantee publication trial results methods since discretion journal editors conference organisers launched online clinical trial register supplement prescribing information publications scientific literature see clinical trial register website register contains results protocol information gsksponsored trials marketed medicines also provides references publications appeared medical journals anyone use internet access register end results clinical trials published site aim post end trial results clinical trials marketed products completed since merger gsk well earlier trials products likely inform medical judgement trial results new products approved marketing posted register time medicine first launched major market maximise access clinical trial data also committed posting trial results phrma clinical trials results database wwwclinicalstudyresultsorg gsk legally required post summary protocol information ongoing studies treatments serious life threatening diseases conducted us investigational new drug application national institutes health website wwwclinicaltrialsgov trials initiate enrolment provides information trial 's purpose contact details information enabling patients investigators take part addition posting summary protocols serious life threatening diseases made additional commitment post summary protocol information gsksponsored clinical trials site facilitate participation enable interested parties track trials taking place subsequent public disclosure results wwwgskcom glaxosmithkline corporate responsibility report dedicated assuring results register posting summary protocol information trials initiating enrolment consistent stated commitments end establishing means providing thirdparty compliance verification information posted public databases agreement principles established conducted assistance external organisation expect complete first full compliance verification exercise q additionally gsk assemble international advisory board provide input matters related public disclosure information arising clinical research activities wwwgskcom glaxosmithkline corporate responsibility report products customers wwwgskcom glaxosmithkline corporate responsibility report products customers marketing marketing training codes practice compliance products products customers corporate responsibility principle promote products line high ethical medical scientific standards comply applicable laws regulations gsk products sold countries around world first priority product country patient safety systems processes collect analyse report safety concerns products approach patient safety please go patient safety website products sold sales representatives regularly meet doctors pharmacists inform medicines approved uses also market products directly consumers permitted sale promotion pharmaceutical products highly regulated governments medical agencies gsk aware sensitivity concerns regarding marketing medicines absolutely committed high ethical standards developed marketing codes policies provide training guide sales representatives ensure behave ethically comply law section explains approach marketing practices covers policies training compliance programmes includes information compliance marketing policies information business ethics issues found standards ethical conduct website wwwgskcom glaxosmithkline corporate responsibility report case study gsk thailand presses higher standards industry thailand industry association prema pharmaceutical research manufacturer association stewardship industry code marketing practices january md gsk thailand rick gain appointed board prema chair sales marketing ethics subcommittee smes time existing marketing practices code three years old made general rather specific commitments rick 's priority reform industry code bringing line us european norms code strengthened number areas example guidance sponsorship overseas conferences strengthened revised code prohibits sponsorship overseas meetings nearly attendees speakers thailand aims prevent overseas travel used inducement conference participants review process took nine months involved gaining agreement major member companies prema new code adopted prema board november memorandum understanding signed member companies commercial staff received training revised code senior members smes december wwwgskcom glaxosmithkline corporate responsibility report products marketing codes practice sales representatives promote products providing information doctors understand products benefits deliver patients marketing policies codes practice give guidance sales marketing employees high ethical standards require codes stress marketing promotion must based valid scientific evidence consistent national prescribing documentation comply law inducements gifts bribes never acceptable circumstances gsk employees must also abide code conduct employee guide business conduct employee guide contains specific section covering customers marketplace see code conduct website employee guide business conduct website marketing policies codes practice companywide policy pharmaceutical marketing promotional activity applies employees agents commits us promotional practices ethical responsible principled patientcentred prohibits bribery inducements doctors december introduced regional marketing practices codes europe international japan marketing codes already place us codes apply ethical standards regions reflect differences market structures national healthcare systems laws regulations also adhere international regional industry codes practice include ifpma phrma efpia jpma marketing codes progress gsks regional codes translated major local languages rolled across gsk sales marketing employees access intranet many received printed copies area champions country coordinated distribution training new codes european code practice includes quarterly reporting mechanism markets confirm whether breaches code practice occurred severity breaches actions taken prevent recurrence wwwgskcom glaxosmithkline corporate responsibility report also developed distributed new guide us healthcare law us pharma employees information previously provided training new guide provides concise easytoread overview complex legal requirements applicable health care businesses us guide supports commitment ethical culture employees good understanding gsks sales marketing policies legal framework behind compliance policies procedures formal performance objective sales marketing employees us evaluated part employee performance reviews us pharma employees must include following objective consistently follow company policies procedures take complete required compliance training timely manner report compliance issues manager legal compliance addition managers must include following ensure supervised employees trained company policies procedures taken required training provide oversight direction supervised employees compliance company policies procedures objectives plan analyse differences amongst gsk international european us codes practice local requirements effort consolidate harmonise codes appropriate us continue enhance compliance programme addition resources act sales marketing compliance advisers advisers work business units ensure compliance ethics policies fully integrated embedded wwwgskcom glaxosmithkline corporate responsibility report products marketing training compliance recognise strong policies codes practice guarantee employees meet standards commercial pressures complex regulatory environments sometimes present employees difficult ethical dilemmas provide regular training sales marketing employees reinforces importance ethical conduct helps understand behaviour expected internal compliance systems designed identify address breaches codes training awareness sales representatives receive detailed training medicines promote diseases designed treat sales marketing employees also given training appropriate marketing practices obligations responsibilities marketing codes practice varies region employees receive training hired refresher courses ongoing basis progress area champions coordinated training new regional codes information codes added induction training new employees regardless whether sales marketing role sales marketing staff either trained recertified understanding sales marketing code global effort new staff us trained nearly existing staff completed recertification policies sales marketing staff europe trained regional sales marketing code international region training delivered seven regional business units training provided variety ways including selfstudy job training managers webbased learning inhouse courses sales staff required pass test code practice starting sales role us sales marketing employees required assess compliance marketing codes part annual performance wwwgskcom glaxosmithkline corporate responsibility report development plan appraisal encourages employees view compliance integral part overall performance monitoring compliance sales representatives supervised sales managers regularly monitor educational events visits doctors expenses ensure best practices observed supplemented additional monitoring independent staff needed certain areas sales managers directed report issues infractions regional compliance officers senior managers encouraged normal line management channels prerogative making reports directly corporate ethics compliance necessary issues investigated appropriate action determined referral corporate ethics compliance department appropriate employees also encouraged report concerns suspected breaches marketing codes line manager compliance officer confidentially integrity helplines offsite po box us staff local market customer response centres trained deal concerns marketing practices might raised healthcare professionals patients public redirect calls appropriate senior management compliance officer necessary internal audit department also audits sales marketing practices regular audits business specifically result breaches sales marketing codes employees dismissed agreed leave company voluntarily addition cases employees issued written warnings included remedial training cases financial penalties figures form part overall figures reported standards ethical conduct website objectives sales marketing compliance advisers appointed us work business units ensure compliance ethics policies fully integrated embedded compliance analysis reporting group also set us review compliance monitoring auditing investigations data advise gsk management compliance related issues wwwgskcom glaxosmithkline corporate responsibility report caring environment wwwgskcom glaxosmithkline corporate responsibility report environment caring environment ehs management energy climate impact water waste ozone depletion volatile organic compounds product stewardship suppliers compliance verification statement progress towards targets corporate responsibility principle operate environmentally responsible manner systematic management environmental impacts measurement performance setting challenging performance targets improve efficiency activities minimise material energy use waste generated aim find opportunities use renewable materials recycle waste caring environment key element approach corporate responsibility gsk environment health safety ehs plan excellence sets strategy improve performance tenyear period baseline includes interim targets reached end track meet seven ten targets cover important environmental issues including energy water consumption ozone depleting potential global warming potential wastewater quality volatile organic compound emissions nonhazardous waste may achieve three targets hazardous waste recycling ozone depletion potential ancillary equipment end fuller explanation performance provided relevant pages report next year set new targets environment section report th year reported environmental performance legacy companies glaxo wellcome smithkline beecham individually published ehs reports number years prior formation gsk copies reports available corporate register website wwwgskcom glaxosmithkline corporate responsibility report previous years published separate ehs report alongside corporate responsibility report year fully integrated two background information approach managing environmental issues available environment health safety website section website also details corporate responsibility reporting section report website scope data environmental data covers calendar year collected pharmaceutical consumer manufacturing sites biologicals manufacturing sites rd sites well distribution centres major office locations smaller office sales locations include data sites operation part year plan collect energy water waste data smaller offices sales distribution centres phased approach next years however overall environmental impact sites relatively small therefore plan collect environmental data notes attached charts explain scope data collection process parameter detail verification environment health safety sections report externally verified erm environmental resources management web pages verification applies indicated symbol see erms verification statement website wwwgskcom glaxosmithkline corporate responsibility report case study raising childrens awareness environment health safety gsks manufacturing site evreux france set community partnership project schools project environment health safety ehs award scheme encouraged children learn ehs issues important future first year five schools children took part thanks part continued help local offices french education ministry french social health insurance ministry office local association dedicated science schools children entered competition year ehs theme theme waste recycling first prize euros towards school project trip science industry hall paris went team created papier mache educational booklet waste recycling prizewinning entries included game recycling play waste educational film recycling shown awards ceremony theme health hygiene awards scheme helped build enhance gsks reputation local community project first place community partnership category internal awards scheme chief executive officers ehs excellence awards wwwgskcom glaxosmithkline corporate responsibility report environment ehs management environment health safety ehs issues managed integrated system aims ensure issues risks identified standards established training provided targets set audits conducted clearly defined ehs management structure overall responsibility ehs issues rests corporate executive team board board champion ehs jp garnier chief executive officer also corporate responsibility committee corporate ehs department see ehs management organisation website ehs policy ehs vision global ehs standards set overall framework managing ehs issues ehs plan excellence sets strategy improving environmental performance see ehs management system website four sites achieved dual certification international environmental management standard iso international health safety standard ohsas first time one site renew certification one site certified utilities area means pharmaceutical consumer manufacturing sites certified iso ohsas seven sites certified iso working increase site certification expect around third sites certified end would put us position move towards global certification case study eliminating waste chemical production processes verona italy developed process reduces environmental impact producing chemical tested help treat chemotherapyinduced nausea vomiting originally method synthesising chemical required low temperatures produced significant quantities waste byproducts also required use triphosgene toxic reagent must specially transported managed handled original process designed producing small quantities chemical scaled several times produce larger quantities clinical trials process remained unchanged researchers set create efficient process suitable commercial production clinical trials successful innovative new process eliminated need extremely low temperatures saving wwwgskcom glaxosmithkline corporate responsibility report energy number hazardous substances removed process including triphosgene chlorinated solvents silica treatments helped reduce waste cost raw materials innovative development first place green chemistrytechnology category internal awards scheme chief executive officers environment health safety excellence awards wwwgskcom glaxosmithkline corporate responsibility report environment letter vice president ehs year first time gsks environment health safety ehs report fully integrated companys corporate responsibility report gskcom cover issues detail made simpler understand overall approach corporate responsibility see connections many subject areas covered consultation stakeholders helped us identify prime sustainability challenges face climate change impact pharmaceuticals environment sustainable materials consumption begun work developing strategies tackle issues publish plans developed rigorous approach ehs sustainability long term plan excellence fiveyear improvement targets applying throughout operations first fiveyear phase programme complete set new fiveyear targets year help drive business towards sustainability end expand traditional ehs programmes include focus sustainability continued make progress example four additional sites certified ehs management system standards iso ohsas track meet seven ten quantified environmental targets end targets cover important issues including energy water consumption ozone depleting potential global warming potential volatile organic compound emissions wastewater quality waste may achieve three targets hazardous waste recycling ozone depletion potential ancillary equipment end fuller explanation performance provided relevant pages report wwwgskcom glaxosmithkline corporate responsibility report long term plan excellence charts journey begins improving systems progresses leadership ehs performance ultimately brings us closer towards sustainability year programme envisages continuous improvement well identifying specific actions good ehs management performance achieved set challenging sustainability objectives materials efficiency energy efficiency use renewable resources also need look closely interrelations social economic environmental impacts business hope report meets needs stakeholder welcome comments suggestions james hagan phd pe vice president corporate environment health safety wwwgskcom glaxosmithkline corporate responsibility report environment plan excellence ehs plan excellence sets strategy improve ehs performance tenyear period year focus different theme priority develop policies response external challenges climate change september held meeting external stakeholder panel represented government customers suppliers environmental groups others help us identify external challenges three key issues gsk identified pharmaceuticals environment use chemicals climate change response developed following specific objectives work external stakeholders review emerging issues draft position statement pharmaceuticals environment draft position statement use chemicals draft position statement future use energy implement regulatory tracking system ehs made good progress objectives worked environment council get feedback external stakeholders issues relating pharmaceuticals environment use chemicals future use energy following consultation prepared discussion documents three areas began get feedback employees complete position statements areas also established regulatory tracking process alert us emerging ehs issues usa eu network ehs specialists tracks regulations made available database employees ehs responsibilities focus ensuring core programmes place throughout business specific objectives complete implementation ehs management system aligned iso ohsas operations achieve acceptable audit scores operations aim achieve average score least business unit site achieving less achieve published ehs global targets analyse close come meeting strategic objectives originally published ehs plan excellence formalise external stakeholder engagement process review revise necessary ehs plan excellence wwwgskcom glaxosmithkline corporate responsibility report also working develop road map sustainable development outlines key steps need take become environmentally sustainable business commissioned study forum future role pharmaceutical company sustainable society used findings develop draft road map finalised see ehs plan excellence wwwgskcom glaxosmithkline corporate responsibility report environment stakeholder engagement engage range stakeholders help us understand external perspectives identify emerging issues report engagement stakeholders environmental issues see engagement stakeholders details engage stakeholders corporate responsibility issues past held ad hoc stakeholder meetings obtain feedback ehs performance plans september held major workshop external stakeholders help us identify emerging challenges plan establish permanent stakeholder panel provide ongoing advice gsk ehs issues stakeholder workshop identified three key external challenges pharmaceuticals environment use chemicals future use energy worked environment council interview around stakeholder organisations including ngos policy makers regulators customers suppliers trade associations help us develop position statements issues see plan excellence website position statements published also partner number environmental organisations specific areas example commissioned study forum future role pharmaceutical company sustainable society used help us develop road map sustainable development another partnership environmental organisation earthwatch institute europe gsk member earthwatch 's corporate environmental responsibility group also funds earthwatch develop field research conservation projects uk send schoolteachers projects part educational programme first time ran competition select gsk employee participate two week earthwatch expedition overseas many sites also engage stakeholders locally example open days newsletters community projects wwwgskcom glaxosmithkline corporate responsibility report environment audits certification ehs audits carry environment health safety ehs audits assess implementation ehs management system standards audits also assess sites compliance key legislation carried internal auditors certified lead auditors international environmental management standard iso aim conduct ehs audits operational site least every four years carry frequent visits selected sites depending assessment risk issues raised previous audits sites audited including three key office locations two thirds sites achieved acceptable scores define average score across sites audited ten sites belgium germany ireland japan turkey uk us achieved high scores one site uk achieved leadership score see audit achievement website highest scores environmental issues identified number health safety issues require attention see manage health safety website details issues identified sites required develop plans address weaknesses opportunities improve identified audit auditors monitor sites progress implementing plans ehs audit process scoring system refined based experience feedback testing ehs auditing software intranet site help auditors track progress aim fully functional version ready ehs certification four sites achieved dual certification international environmental management standard iso international health safety standard ohsas first time one site renew certification one site certified utilities area means pharmaceutical consumer manufacturing sites certified sites certified iso ohsas seven sites certified iso one sites utility area certified certified sites china egypt france germany india italy mexico poland spain turkey uk working increase site certification expect around third certified end position move towards global certification wwwgskcom glaxosmithkline corporate responsibility report environment environment costs capital investment environmental projects million operating maintenance costs million expenditure relates wastewater treatment waste management air pollution control performance capital investment operations maintenance costs waste waste wastewater wastewater air air decrease capital investment increase operations maintenance costs capital investment decreased since due cost control measures rationalisation manufacturing sites operation maintenance costs cyclical therefore vary year year wwwgskcom glaxosmithkline corporate responsibility report environment training awareness wide range awarenessraising training initiatives ehs supported detailed ehs section intranet called myehs includes policies standards guidelines tools examples best practice news see myehs website chief executive officers ehs excellence awards scheme recognises outstanding efforts ehs helps raise profile ehs issues around business prepare regular ehs bulletins distributed sites posting bulletin boards three bulletins circulated also include articles ehs internal magazine gsk spirit manufacturing magazine site newsletters gsk two key awareness raising events environment week held every june coincide world environment day annual health safety week held every october coincide european health safety week fire safety awareness month united states information kits sent sites help develop ideas plan activities employees sites countries took part environment week examples activities included tree planting computer recycling car day pledges reduce energy use also ran competition earth week best environmental initiative funded winner twoweek conservation expedition run earthwatch see manage health safety case study website health safety week summer held annual regional meetings ehs professionals manufacturing share information best practice events attended ehs professionals ehs training takes place site level accordance ehs standard training range training materials available intranet site see ehs communication website wwwgskcom glaxosmithkline corporate responsibility report environment ehs excellence awards chief executive officers environment health safety ehs excellence awards programme run third year recognises rewards gsk sites innovation ehs winners chosen panel includes experts academia government ngos three categories awards community partnership green chemistrygreen technology ehs initiative award including separate awards environment safety winner receives trophy selects charity receive donation entries gsk sites countries entries previous year awards recognise achievements calendar year winners ehs community partnership st place evreux france ehs school challenge gsk business division global manufacturing supply new product global supply ehs school challenge aims raise awareness ehs issues among local school children fourteen schools took part initiative see case study website nd place xochimilco mexico working neighbours gsk business division pharmaceuticals international global manufacturing supply regional pharma supply site supports range projects help mixteca ethnic communities examples include training four thousand health promoters supporting clinic cervicaluterine cancer assisting local women establish chicken farm food income rd place sonepat india project pragati gsk business division global manufacturing supply consumer healthcare supply project pragati pragati means development provides support local communities including eye clinic address high incidence eye problems area training village women seamstresses traffic pedestrian safety education sessions helping fund fire engine green chemistry technology st place verona italy environmentally friendly synthesis gwb gsk business division research development novel techniques used remove several hazardous substances including triphosgene production process gwb tested prevent chemotherapyinduced nausea vomiting see case study website nd place cork eire gw solvent usage reduction project wwwgskcom glaxosmithkline corporate responsibility report gsk business division global manufacturing supply primary supply antibiotics research development reduction solvent use energy savings achieved redesigning process making gw used treat solid tumours rd place stevenage united kingdom development gw route manufacture gsk business division research development new process developed produce gw used treatment migraines avoids use dioxane carcinogenic chemical eliminates use dmf solvent listed reproductive hazard solvent emissions directive also saves energy reduces waste overall improvements process reduced costs per kg annual saving million based projected peak production tonnes per year ehs initiative environment st place bogot colombia pharmaceutical waste bioremediation gsk business division global manufacturing supply consumer healthcare supply pioneering use reed bed technology treatment pharmaceutical waste colombia led reduction cost final waste treatment see case study website nd place cairo egypt waste reuse reduced resource consumption gsk business division global manufacturing supply regional pharma supply new process designed reuse waste gelatine encapsulation process reducing waste resource consumption rd place barnard castle united kingdom increased mass conversion efficiency cephalosporin oral products gsk business division global manufacturing supply new product global supply improvements process producing cephalosporin antibiotic significantly reduced amount waste helping divert tonne per year active pharmaceutical ingredient incineration ehs initiative safety st place barnard castle united kingdom ergonomic improvements gsk business division global manufacturing supply new product global supply site successfully raised employee awareness ergonomic risks teams identified completed ergonomic improvement projects ergonomic experts consulted design new equipment see case study website nd place nabha india ehs strategy mechanical scraping machine wwwgskcom glaxosmithkline corporate responsibility report gsk business division global manufacturing supply consumer healthcare supply site produces malted food implemented new ehs strategy resulted development new mechanised scraping machine used tray drying process reduced workers exposure moving parts risk repetitive strain injury rd place mayenne france control driving risks gsk business division global manufacturing supply primary supply antibiotics site organised driving safety courses employees five years year employees complete oneday training session including classroom presentations practical workshops drivers learn control cars emergencies see ceos ehs excellence award website awards programme winners previous years wwwgskcom glaxosmithkline corporate responsibility report environment energy climate impact increase greenhouse gases atmosphere widely thought climate scientists causing rise earths temperature leading climate change burning fossil fuels heat power releases carbon dioxide co significant greenhouse gas gsks climate impact comes energy use facilities transport compounds use contribute global warming biggest source energy use facilities two thirds target reduce global warming potential energy per unit sales baseline track meet target see energy report compounds contribute global warming used production metered dose inhalers ancillary equipment include cfcs hcfcs also deplete ozone layer hfcs deplete ozone layer emissions ozone depleting compounds also reported ozone depletion section report see product stewardship report use ozone depleting compounds products wwwgskcom glaxosmithkline corporate responsibility report carbon dioxide methane waste treatment fermentation also contribute global warming impact report performance waste section report performance global warming potential global warming potential decreased since note global warming charts global warming impact energy calculated using conversion factors world business council sustainable development wbcsd world resources initiative wri greenhouse gas protocol initiative september stationary mobile combustion workbooks intergovernmental panel climate change use conversion factors uk department environment food rural affairs calculate co business air travel air freight energy use facilities includes energy consumed gsk facilities form electricity imported steam imported fuels burned fixed combustion equipment site including emergency generators figures include fuels used generate steam electricity site fuel onsite transport energy consumption section report includes breakdown energy data transport includes business travel air including transatlantic flights wwwgskcom glaxosmithkline corporate responsibility report us uk flights within eu us routine business activities flights originating uk large group events sales conventions business travel road including companyowned vehicle fleets primarily global sales fleet product freight air increase global warming potential transport since mainly improved reporting systems comprehensively collect transport data example data include business air travel within eu us include uk international sales fleet miles data include employee travel work collect data modes business travel including rail bus calculate co emissions road rail sea freight transport central data collection system robust areas impacts small compared air freight transport transport section report includes breakdown transport data compounds contribute global warming used production metered dose inhalers ancillary equipment include cfcs hcfcs also deplete ozone layer hfcs deplete ozone layer ozone depletion section report contains breakdown ozone depleting gases data include cfcs released patient use metered dose inhalers co equivalents waste treatment fermentation wwwgskcom glaxosmithkline corporate responsibility report environment energy consumption energy use facilities accounts gsks global warming impact used million gigajoules energy equivalent energy consumed one year approximately uk households produced emissions million kg co bought energy electricity small amount municipal steam hot water rest generated fuel combustion onsite developed draft position statement future use energy finalised response feedback showing energy use key area concern among stakeholders draft position sets strategy reducing greenhouse gas emissions energy efficiency renewable energy emissions trading also acknowledges climate change may affect disease patterns proposes gsk support research help society plan consequences climate change continued work number energy efficiency initiatives example uk gsk partnered carbon trust reduce energy consumption energy audits raising employees awareness us joined energy star programme encourages businesses increase energy efficiency share best practice uk installed two wind turbines barnard castle facility number uk sites participating government 's emissions trading scheme ets helping us gain experience carbon trading uk ets voluntary scheme rewards companies improve energy efficiency reductions tax pay energy consumption sites keep emissions agreed target bank spare credits help compliance subsequent years sell credits participants scheme end gsk banked carbon credits used help us keep within targets future plan participate eu emissions trading scheme began start estimate carbon dioxide emissions energy worldwide regulated eu scheme wwwgskcom glaxosmithkline corporate responsibility report performance energy consumption excluding transport targets nontransportfuels electricityimported steam imported per unit sales percentage baseline energy consumption business excluding transport rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial million gigajoules total energy consumption decreased since since energy consumption per unit sales increased since however decreased since expect meet target reduction per unit sales since wwwgskcom glaxosmithkline corporate responsibility report global warming potential energy excluding transport targets electricity nontransportfuels steamimported per unit sales percentage baseline global warming potential energy business excluding transport rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial million kg co equivalent total global warming potential energy use facilities decreased since since global warming potential per unit sales increased since decrease since meaning track meet target reduction per unit sales since sulphur dioxide nitrogen oxides wwwgskcom glaxosmithkline corporate responsibility report kilograms kilograms x emitted figures calculated coal used gsk manufacturing plants energy source note energy charts energy consumption facilities defined energy consumed form electricity imported steam imported fuels burned fixed combustion equipment site including emergency generators figures include fuels used generate steam electricity onsite fuel site transport global warming potential energy use facilities calculated using conversion factors world business council sustainable development wbcsd world resources initiative wri greenhouse gas protocol initiative september stationary mobile combustion workbooks intergovernmental panel climate change calculated coal used gsk facilities x primarily india energy purposes using conversion factors national atmospheric emissions inventory uk national methodology wwwgskcom glaxosmithkline corporate responsibility report environment transport estimate transport accounts total global warming impact emitted approximately million kilograms co transport business air travel accounts half travelrelated co emissions employees travelled total million kilometres plane resulting million kg co emissions includes transatlantic flights us uk flights within eu us routine business activities well travel originating uk related large group events sales conventions global sales fleet excluding uk drove total million kilometres business travel resulting million kg co addition business travel also transport products manufacturing plants distributors gsk products transported total million kilometres majority air freight estimate air freight resulted million kg co calculate co emissions road rail sea freight transport central data collection system robust areas impacts small compared air freight transport green travel plans number sites encourage employees reduce environmental impact travel work example gsk house brentford uk privileged parking spaces given carsharers drivers fuel efficient cars buses run local train station changing rooms showers provided cyclists well discounts bicycle equipment repairs encourage employees use video teleconferencing possible reduce air travel virtual meeting software available employees making presentations email internal messaging system widely used although difficult quantify impact reducing business travel wwwgskcom glaxosmithkline corporate responsibility report performance global warming potential transport businesstravelbyroad businesstravelbyair productfreightbyair total global warming potential transport increased since since increase since mainly improved reporting systems comprehensively collect transport data example data include business air travel within eu us include uk international sales fleet miles estimate still underestimating global warming potential transport robust system collect uk sales fleet travel group air travel originating uk note transport chart data business air travel includes transatlantic flights us uk flights within eu us routine business activities flights originating uk large group events sales conventions data business travel road global sales fleet except uk sales fleet collect data modes business travel including rail bus co air freight covers global routes calculate co emissions road rail sea freight transport central data collection system robust areas impacts small compared air freight transport use conversion factors uk department environment food rural affairs calculate co business air travel air freight wwwgskcom glaxosmithkline corporate responsibility report environment water water valuable natural resource needs conserved protected pollution water conservation particularly important areas water shortages common gsk uses water manufacturing eg processes products cooling cleaning general site uses including food services sanitation operate several areas world classified waterstressed sites water stressed areas areas classified highly stressed world resources institute used million cubic metres water decrease since since water consumption per unit sales decreased since since meaning exceeded target reduction per unit sales since generated million cubic metres wastewater reused recovered recycled assess quality wastewater measuring chemical oxygen demand cod oxygen required chemically oxidise organic inorganic compounds present water total cod decreased since since cod per unit sales decreased since since meaning track meet target reduction per unit sales since wwwgskcom glaxosmithkline corporate responsibility report environment water use used million cubic metres water equivalent water used one year approximately uk households sourced municipal water supplies wells boreholes sources five sites india use processed wastewater watering plants trees help provide shade improve appearance site also source food employees discharge wastewater water bodies municipal sewers site xochimilco mexico uses processed wastewater watering gardens around site washing vehicles windows uses requiring drinking water sites turkey philippines also reuse wastewater performance water consumption targets wellsboreholes municipal sources per unit sales percentage baseline wwwgskcom glaxosmithkline corporate responsibility report water consumption business rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial million cubic metres total water consumption decreased since since water consumption per unit sales decreased since since meaning exceeded target reduction per unit sales since note water use charts water use includes water sourced wellsboreholes municipal sources mainly wastewater external industrial sources data include water used manufacturing processes general sites uses well water incorporated products wwwgskcom glaxosmithkline corporate responsibility report environment wastewater generated million cubic metres wastewater manufacturing processes various site operations total wastewater reused recovered recycled five sites india implemented zero wastewater discharge programmes reusing recycling wastewater another three sites mexico philippines turkey also reuse wastewater assess quality wastewater measuring chemical oxygen demand cod oxygen required chemically oxidise organic inorganic compounds present water one site brasov romania fined rol local water company exceeding cod limit performance wastewater volume million cubic metres river wwwgskcom glaxosmithkline corporate responsibility report wastewater volume business rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial million cubic metres total wastewater volume decreased since since wastewater chemical oxygen demand targets per unit sales percentage baseline includes reusedrecoveredrecycled onsite irrigation incineration wwwgskcom glaxosmithkline corporate responsibility report wastewater chemical oxygen demand business rd biologicals consumer healthcare newproduct andglobalsupply regional pharmasupply primary supply antibiotics commercial million kg total cod decreased since since decrease site ulverston uk outsourced fermentation process cod per unit sales decreased since since meaning track meet target reduction per unit sales since note wastewater cod charts wastewater volume includes manufacturing site process wastewater well sanitary food service wastewater wastewater quality measured chemical oxygen demand cod measure oxygen required chemically oxidise organic inorganic compounds present water cod measured wastewater leaves sites following site treatment began ask sites submit cod data following municipal treatment takes account final treatment occurring municipal publiclyowned wastewater treatment works therefore gives better indication impact operations final receiving waterways however many sites submitted data means data still primarily reflects cod onsite treatment revisit parameter scope develop new ehs metrics targets wwwgskcom glaxosmithkline corporate responsibility report environment waste waste includes hazardous waste mostly waste solvents non hazardous waste mostly general site waste report nonroutine waste mostly construction demolition waste separately fluctuates depending building works remediation projects active ingredients pharmaceutical products manufactured using synthetic chemistry processes means significant proportion waste contains solvents chemicals used processes classified hazardous disposed million kg nonhazardous waste million kg hazardous waste nonhazardous waste disposed per unit sales increased since decreased since meaning exceeded target reduction per unit sales since hazardous waste disposed per unit sales increased since since meaning track meet target reduction per unit sales since due combination factors described hazardous waste section many sites introduced waste minimisation recycling initiatives recycled million kg waste total waste generated proportion waste recycled decreased since since meaning track meet target increase proportion waste recycled since production changes led greater proportion solvent waste blended fuel incinerated less recycled large number projects related waste issues total submitted gsk ceo ehs excellence awards site bogot colombia awarded st place environment category awards pharmaceutical waste bioremediation project see case study wwwgskcom glaxosmithkline corporate responsibility report case study developing environmentally friendly ways disposing unused pharmaceutical products consumer healthcare site bogot colombia developed system reduce environmental impact disposing unused liquid pharmaceutical products including product returns rejects liquid waste treated reed beds although reed beds becoming increasingly popular treat domestic industrial wastewater colombia team pioneers using treat pharmaceutical waste reeds usually phragmites australis planted specially designed soil beds provide ideal environment bacteria fungi break hazardous chemicals naturally harmless components reeds absorb chemicals waste nutrients initial trial treating mixture waste syrup used oil levels chemicals residual water reed beds fell legal limits days system replaces high temperature incineration energy intensive dispose certain wastes syrups effectively using reed beds reduced cost final disposal per kilogram product building reed bed treatment plant bogot site feasible enough space team promoted idea joint initiative companies june waste treatment company transform ecoskandia ltda financial partners founded transform biolodos ltda build first large reed bed plant colombia industrial public use bogot site first place environment category internal awards scheme chief executive officers environment health safety excellence awards site closed reed bed treatment plant used several major companies wwwgskcom glaxosmithkline corporate responsibility report environment hazardous waste disposed million kg hazardous waste excluding demolition construction waste mostly solvents rest general site waste chemical biological radioactive waste hazardous waste disposed incinerated energy recovery incinerated without energy recovery remaining waste disposed licensed landfill sites performance hazardous waste disposed hazardous waste source targets incineratedwithoutenergyrecovery incineratedwithenergyrecovery landfill per unit sales percentage baseline wwwgskcom glaxosmithkline corporate responsibility report hazardous waste disposed business rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial million kg total hazardous waste disposed increased since since hazardous waste disposed per unit sales increased since since meaning track meet target reduction per unit sales since previous trend reducing hazardous waste per unit sales reversed combination factors gsks hazardous waste mostly solvents one plant scheduled closure dispose redundant solvent stocks one impact data addition changes production plants included bringing inhouse processes previously undertaken contract manufacturers engineers assessing optimise new processes reduce solvent use increase recycling note hazardous waste charts although external definition constitutes waste varies gsk reporting purposes material considered waste longer fit originally intended purpose hazardous waste disposed includes disposal landfill incineration either gsk property incineration energy recovery includes processes result beneficial energy resource recovery includes small amount composting incineration without energy recovery includes processes result beneficial energy resource recovery hazardous waste disposed include recycling onsite offsite nonroutine waste consistent reporting gsk considers waste hazardous exhibits number properties defined basel convention wwwgskcom glaxosmithkline corporate responsibility report united nations environment programme unep included properties flammability explosivity water air reactivity corrosivity oxidising potential acute chronic toxicity ecotoxicity infection addition nature potential impact research development activities radioactive wastes defined hazardous bioengineered biohazardous waste included hazardous waste waste considered nonhazardous exhibit hazardous properties noted wwwgskcom glaxosmithkline corporate responsibility report environment nonhazardous waste disposed million kg nonhazardous waste excluding nonroutine waste equivalent waste produced approximately uk households nonhazardous waste general site waste office waste paper kitchen waste nonhazardous substances used manufacturing many sites continue look ways reduce waste undertaken waste management reviews performance nonhazardous waste disposed nonhazardous waste source targets incineratedwithoutenergyrecovery incineratedwithenergyrecovery landfill per unit sales percentage baseline wwwgskcom glaxosmithkline corporate responsibility report nonhazardous waste disposed business rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial million kg total nonhazardous waste disposed decreased since since nonhazardous waste disposed per unit sales increased since decreased since meaning exceeded target reduction per unit sales since note nonhazardous waste charts although external definition constitutes waste varies gsk reporting purposes material considered waste longer fit originally intended purpose nonhazardous waste disposal includes disposal landfill incineration either gsk property incineration energy recovery includes processes result beneficial energy resource recovery includes small amount composting incineration without energy recovery includes processes result beneficial energy resource recovery non hazardous waste disposed include recycling onsite offsite nonroutine waste biological waste rendered nonhazardous treatment considered non hazardous waste wwwgskcom glaxosmithkline corporate responsibility report environment recycling recycled million kg waste million kg waste generated total waste recycled hazardous waste primarily solvents new recycling programmes led significant reductions waste several sites example cidra puerto rico recycling range materials reduced nonhazardous waste disposed landfill per year clifton new jersey us recycling plastic packaging materials saved metric tonnes waste per year performance proportion total waste total waste recycled recycled targets waste recycled per unit sales percentage baseline wwwgskcom glaxosmithkline corporate responsibility report proportion total waste recycled business rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial total waste recycled decreased since since proportion waste recycled decreased since since meaning track meet target increase proportion waste recycled since production changes led greater proportion solvent waste blended fuel incinerated less recycled note recycling charts waste recycled includes hazardous nonhazardous waste non routine waste reused recovered recycled site site includes inprocess reuse solvents wwwgskcom glaxosmithkline corporate responsibility report environment nonroutine waste nonroutine waste primarily demolition construction waste includes hazardous nonhazardous waste site demolition construction activities small onsite remediation projects disposed via landfill incineration million kg nonroutine waste recycled million kg performance nonroutine waste incineratedwithoutenergyrecovery incineratedwithenergyrecovery landfill recycled total nonroutine waste disposed decreased since since amount waste fluctuates year depending plant upgrades site closures note nonroutine waste charts although external definition constitutes waste varies gsk reporting purposes material considered waste longer fit originally intended purpose nonroutine related waste disposal includes disposal landfill incineration either gsk property incineration energy recovery includes processes result beneficial energy resource recovery includes small amount composting incineration without energy recovery includes processes result beneficial energy resource recovery non routine waste disposed include waste recycled onsite offsite wwwgskcom glaxosmithkline corporate responsibility report environment ozone depletion ozone layer essential human survival filters harmful ultraviolet uv rays sun ozone depleting substances odss include chlorofluorocarbons cfcs hydrochlorofluorocarbons hcfcs halons cfcs main ods use propellant gas metered dose inhalers mdi asthma sufferers cfc released patients use inhaler thousand kilograms cfc propellant released patients used products eu us much smaller amount cfcs thousand kilograms released worldwide production information cfc releases compiled outside us uk required regulation offer selection alternatives odscontaining inhalers countries plan eliminate use odss product portfolio see metered dose inhalers ozone depletion potential production per unit sales decreased since meaning exceeded target reduction per unit sales since also use odss cooling systems ancillary uses gsk facilities switched using hydrofluorocarbons hfcs cooling systems hfcs deplete ozone layer contribute global warming ozone depletion potential ancillary use per unit sales decreased since current trend indicates may miss target eliminate emissions plan establish team develop business strategy eliminate ancillary emissions odss wwwgskcom glaxosmithkline corporate responsibility report environment ozone depleting substances manufacturing small proportion cfc used manufacture metered dose inhalers mdis released manufacturing process working eliminate use ozone depleting substances odss mdis switching hfc dry powder inhalers see metered dose inhalers report performance ozone depletion potential production use targets production per unit sales percentage baseline wwwgskcom glaxosmithkline corporate responsibility report ozone depletion potential production use business rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial thousand kg cfc equivalent ozone depleting substances released production activities substance kg factor ozone depletion potential cfcr cfcr trichloroethane methyl bromide total ozone depletion potential production decreased since since ozone depletion potential production per unit sales decreased since since meaning exceeded target reduction per unit sales since production cfccontaining mdis decreases amount cfc lost production also declines longer manufacture cfc containing mdis us europe continue manufacture bangladesh china india pakistan end note ozone depletion potential charts report ozone depletion potential cfc equivalents defined united nations environment programme unep ozone secretariat wwwghgprotocolorg wwwipccch wwwgskcom glaxosmithkline corporate responsibility report environment ozone depleting substances ancillary equipment use ozone depleting substances odss primarily cooling systems switched using hydrofluorocarbons hfcs ancillary equipment hfcs deplete ozone layer contribute global warming odss mainly hcfcs sealed inside cooling systems released event leak maintenance plan establish team develop business strategy eliminate ancillary emissions odss closely monitor equipment put place recommendations alternative refrigerants new equipment performance ozone depletion potential ancillary use targets ancillary per unit sales percentage baseline wwwgskcom glaxosmithkline corporate responsibility report ozone depletion potential ancillary use business rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial thousand kg cfc equivalent ozone depleting substances released ancillary activities substance kg factor ozone depletion potential cfcr cfcr hfcr hfcr ra rafx rafx r r total ozone depletion potential ancillary use change decreased since ozone depletion potential ancillary use per unit sales increased since decreased since current trend indicates may miss target eliminate ozone depleting emissions ancillary use proved possible eliminate emissions servicing maintenance cooling equipment means need upgrade replace equipment use nonozone depleting gases new cooling systems introduced dont use ozone depleting gases however upgraded replaced equipment note ozone depletion potential charts report ozone depletion potential cfc equivalents defined united nations environment programme unep ozone secretariat wwwghgprotocolorg wwwipccch wwwgskcom glaxosmithkline corporate responsibility report environment volatile organic compounds use volatile organic compounds vocs mainly solvents primary manufacturing operations released million kilograms vocs atmosphere vocs react nitrogen oxides presence sunlight creating ozone lower atmosphere results smog factor human respiratory illness workplace exposure certain vocs also pose health risk performance volatile organic compounds emitted air targets voc per unit sales percentage baseline wwwgskcom glaxosmithkline corporate responsibility report volatile organic compounds emitted air business rd biologicals consumer healthcare new product global supply regional pharma supply primary supply antibiotics commercial million kg photochemical ozone creation potential total vocs emitted air decreased since since vocs emitted air per unit sales decreased since since meaning track meet target reduction per unit sales since photochemical ozone creation potential decreased since since wwwgskcom glaxosmithkline corporate responsibility report note voc charts emissions volatile organic compounds vocs measured gsk manufacturing operations research development facilities including fugitive sources evaporation leaks vocs react nitrogen oxides presence sunlight creating ozone lower atmosphere results smog factor human respiratory illness report photochemical ozone creation potential pocp ethylene equivalents conversion ethylene equivalents based european chemical industry council cefic responsible care hse reporting guidelines vocs case study reducing solvent emissions ulverston uk use widerange solvents volatile organic compounds manufacture epivir antiretroviral zinacef zinnat cephalosporin antibiotics site ulverston uk endeavour use solvents sustainable manner tonnes solvent recovered year ulverston site reuse manufacturing processes working number years reduce releases solvents including dichloromethane site february site produced solvent management plan substitution plan line requirements new eu regulations updated july site authorised uk environmental protection act release maximum tonnes dichloromethane air emissions air totalled tonnes well limit reduction compared period releases vocs reduced declined last fiveyears target reduce emissions dichloromethane air less tonnes tonnes also reduced amount dichloromethane discharged water compared aim reduce amount one tonne tonnes dichloromethane continues used enclosed equipment regular monitoring employees ensures exposure levels remain low levels solvents including dichloromethane found around edge site well guide limits set environment agency england wales wwwgskcom glaxosmithkline corporate responsibility report environment product stewardship well managing environmental issues factories look widely lifecycle products product design use eventual disposal call product stewardship section focuses product design incorporating environmental considerations design new products pharmaceuticals environment understand minimise impact pharmaceuticals released environment following use cfcs metered dose inhalers progressing target eliminate use cfcs ozone depleting gas product portfolio number environmental issues associated products including use genetically modified organisms use natural resources may impact biodiversity see approach biodiversity genetically modified organisms gsk website research development section report covers approach animal testing wwwgskcom glaxosmithkline corporate responsibility report environment product design working incorporate environmental considerations design new products helps us reduce waste improve process efficiency ecodesign toolkit alerts us potential ehs issues early development process includes green chemistry guide materials guide green packaging guide flasc fast lifecycle assessment synthetic chemistry available intranet made progress integrating ehs milestone aligned process ehs map product development supply processes including design manufacturing initiative approximately employees rd manufacturing attended training sessions ehs map process year see business processes ehs map see approach product design gsk website wwwgskcom glaxosmithkline corporate responsibility report environment pharmaceuticals environment patients use pharmaceuticals active ingredient may completely metabolised generally excreted wastewater treatment plants remove pharmaceutical residues environment small concentrations end rivers sea areas without wastewater treatment higher concentrations released environment following consultation external stakeholders developed draft position statement pharmaceuticals environment completed internally developed business processes ensure carry appropriate environmental tests since environmental risk assessments eras part new drug approval process eu us work various regulatory agencies ensure potential environmental impacts pharmaceuticals understood minimised also work pharmaceutical companies universities research groups develop science methodologies assess environmental risks pharmaceuticals environment increase understanding risks example us gsk involved pharmaceutical research manufacturers america phrma developing phate pharmaceutical assessment transport evaluation model geographically explicit model based hydrology population patterns see approach pharmaceuticals environment gsk website initiated comprehensive environmental risk assessments using phate model active pharmaceutical ingredients apis including paroxetine active ingredient paxilseroxat assessments published website underlying environmental fate effects test data pharmaceutically active components gsk marketed products embedded safety data sheets sds available website wwwmsdsgskcom risk assessments carried date indicate products appear pose risk humans environment based current methods ascertaining effect levels however continue monitor latest scientific studies findings improve risk assessments area wwwgskcom glaxosmithkline corporate responsibility report environment metered dose inhalers metered dose inhalers mdis first introduced used one main forms treatment asthma sufferers pressurised handheld devices use propellants deliver doses medication lungs patients cfcs traditionally used propellant nontoxic nonreactive nonflammable odour taste free patient uses mdi propellant released atmosphere thousand kilograms cfc propellant released patients used products eu us much smaller proportion cfcs thousand kilograms escaped production see ozone depleting substances manufacturing gsk website although montreal protocol bans production cfcs recognise number essential uses exempt ban mdis fall essential use exemption therefore still allowed manufactured plan eliminate use cfcs product portfolio offer selection alternatives cfccontaining mdis countries main alternative propellant use hfc also invested heavily dry powder delivery systems use cfcs estimate total amount spent new plant rd cfc alternatives million billion since identified issue also researching alternatives hfca high global warming potential wwwgskcom glaxosmithkline corporate responsibility report performance ozone depletion potential patient use metered dose inhalers decreased since since note ozone depletion potential charts report ozone depletion potential cfc equivalents defined united nations environment programme unep ozone secretariat wwwghgprotocolorg wwwipccch data include eu us wwwgskcom glaxosmithkline corporate responsibility report environment suppliers supply chain complex ranges major strategic relationships contract manufacturers make final medicines us suppliers key materials ehs standards suppliers also include ehs requirements based standards initial agreements new key suppliers renew contracts conduct regular ehs audits key suppliers assess performance ehs standards key legislation also carry ehs audits start working major new suppliers select suppliers audit basis risk including potential hazards audits also cover basic questions human rights see human rights suppliers gsk website carried sitebased ehs audits sixteen audits asia eleven europe six us one canada one mexico also carried four followup reviews found wide variation performance across sites audited lowest score highest make recommendations sites following audits process monitor progress particular focus poorly performing sites three potential suppliers achieved unacceptable ehs scores less therefore source existing supplier scored developed action pack use procurement managers help identify ehs risks associated procurement activities us signed green suppliers network gsn programme run us environment protection agency help small medium sized suppliers reduce environmental impact encourage suppliers participate project key audit findings environment found basic elements environmental management system sites audited chemical sites certified international environmental management standard iso sites good understanding environmental regulations positive relationships regulators wwwgskcom glaxosmithkline corporate responsibility report china india generally found high level compliance regulations effective management waste water however lack infrastructure countries presents challenges example waste disposal options limited electricity generated mainly coal poorquality oil also found air emissions poorly controlled cases health safety found health safety generally well managed sites europe north america however identified challenges emerging economies especially areas relating fire prevention response occupational hygiene control chemical exposure identification hazards risks systems reporting investigating incidents wwwgskcom glaxosmithkline corporate responsibility report environment supplier performance approximately centrally managed key suppliers include contract manufacturers suppliers materials working towards quantifying environmental impact contract manufacturers difficult process collecting data sites contract manufacturers independently managed collected data major contract manufacturers core ehs parameters contract manufacturers produced kilograms product gsk including raw materials primary secondary manufacturing secondary packaging disposed million kilograms hazardous waste million kilograms nonhazardous waste used gigajoules energy related energy transport activities gigajoules electricity gigajoules nontransport fuels gigajoules transport fuels data companies included charts included verification erm see health safety suppliers contractors wwwgskcom glaxosmithkline corporate responsibility report environment compliance minimum aim comply legal requirements environment health safety environmental fines penalties brasov romania rol approximately local water company exceeding cod limit zebulon us approximately local wastewater authority exceeding permitted discharge limit cyanide clifton us notices violation without fines ph excursions one occurred zebulon us notices violation without fines ph mercury cyanide memphis us hazardous waste inspection resulted minor violations ware gms uk unlicensed discharge ipc al licensed processes health safety fines penalties clifton us approximately osha fine machine guarding incident wwwgskcom glaxosmithkline corporate responsibility report environment verification statement erm environmental resources management limited asked gsk independently review environment health safety ehs sections corporate responsibility report section employment practice section caring environment supporting background information provided gskcom fourth year erm verified gsks ehs reporting objectives review check information presented accurate represents gsks performance fairly critically review completeness relevance information presented assess effectiveness gsks data management systems pages contain verified ehs data marked following symbol focused understanding gsks ehs data management reporting processes ehs performance assessment covered percent gsk manufacturing sites percent rd facilities expanding erms coverage sites compared overall findings subject comments scope set believe gsks corporate responsibility report covers key ehs issues interested parties need know inform decision making ie relevant avoid major issues ie complete fairly reflects programmes performance ground ie accurate erm scope november march erm reviewed ehs data management reporting processes performance changes crosssection sites four site visits telephone interviews interviewed personnel responsible data collation corporate ehs cehs checked sample group data interviewed corporate representatives obtain supporting information following ehs programmes acquisitions divestitures contaminated land climate change ozone depleting potential auditing suppliers contract manufacturers ehs reporting commercial business support team wwwgskcom glaxosmithkline corporate responsibility report participated final cehs datachecking review process undertaken sites submitted ehs data checked ehs sections corporate responsibility report reflect findings findings relevance completeness overall ehs sections corporate responsibility report cover key issues relevant gsks business year erm makes recommendations improvement response erm recommendation made sustainability environment health safety report gsk attempted collect information reasons changes site ehs performance erm noted improvement gsks reporting reasons performance change ehs report sections also noted progress made relation gsks reporting transportrelated greenhouse gas emissions gsk obtained ehs performance data contract manufacturers versus seven part effort quantify gsks broader ehs footprint gsk focused collecting key ehs indicator data businesscritical contract manufacturers data verified erm accuracy year corporate data checking processes strengthened increase quality data involvement additional gsk personnel erms participation final checking process gsk also observed erms verification process one site visit next year gsk proposes use myehs database system track datachecking actions site seen examples increased reporting illness injury data sites may part due improved awareness result introduction myehs incidents database associated training provided gsk personnel approximately sites erm identified three material data inaccuracies relating wastewater quality cod wastewater volume production use ozone depleting substances subsequently addressed gsk ensure accurate reporting corporate responsibility report erm identified potentially material underreporting ehs data particular injury illness data gsks commercial business includes office based field salesforce staff responsiveness gsk reported stakeholders would like gsk prepare combined corporate responsibility report incorporating ehs would like better understand management performance number nonfinancial wwwgskcom glaxosmithkline corporate responsibility report issues response gsk produced single webbased corporate responsibility report process preparing position papers selection issues eg climate change recommendations erm recommends gsk builds work undertaken strengthen internal reporting processes better understand reasons ehs performance changes enable consistent explicit external reporting improves collection reporting performance data contract manufacturers suppliers focussing business critical greatest ehs risk profile improves accuracy environmental key performance data comprehensively checking completeness data reported operations supports key operations accurately monitor material flows discharges related key environmental performance indicators assesses potential material data inaccuracies resulting underreporting gsks commercial operations puts place improvement programmes obtain complete data set reviews limitations ehs performance data particular potential scale statistical uncertainty targetrelated key ehs performance data including transport derived emissions greenhouse gases erm march wwwgskcom glaxosmithkline corporate responsibility report environment progress towards targets ehs plan excellence sets strategy improve performance tenyear period starting baseline includes interim targets reached end track meet seven ten targets cover important environmental issues including energy water consumption ozone depleting potential global warming potential wastewater quality volatile organic compound emissions nonhazardous waste may achieve three targets hazardous waste recycling ozone depletion potential ancillary equipment end fuller explanation performance provided relevant pages report next year set new targets group targets based improvement plans forecasts sites year asked sites reconfirm commitment targets set see approach setting targets summary environmental performance per unit sales graph shows overall improvement since targets performance summary expressed change baseline energyconsumption nonhazardous globalwarming wastedisposed potentialenergy hazardous wastedisposed odpancillary reductioninwastedisposed dueto recycling odpproduction cod vocs waterconsumption wwwgskcom glaxosmithkline corporate responsibility report managing cr wwwgskcom glaxosmithkline corporate responsibility report managing corporate responsibility cr principles management managing corporate responsibility governance gsks corporate responsibility committee consists nonexecutive directors provides boardlevel forum regular review external issues potential serious impact upon gsks business oversight reputation management provides highlevel guidance approach cr issues committee met three times reviewed activity number areas including access medicines research development disease developing world charitable giving committee effectiveness gsks risk oversight compliance council coordinates internal control management significant risks business council considers reputational corporate responsibility risks information crc council including terms reference crc see corporate governance wwwgskcom glaxosmithkline corporate responsibility report integration cr skills believe daytoday management corporate responsibility performance done effectively within business operations experts cr issues work coordination provided crossfunctional team made representatives key business areas role oversee development implementation communication cr policy across gsk ensures comprehensive consistent approach taken throughout organisation also small corporate team coordinates policy development reporting communication socially responsible investment analysts details ehs management see ehs management stakeholder engagement frequent discussions range stakeholders including employees shareholders patients doctors governments ngos inform approach managing corporate responsibility see engagement stakeholders developed corporate responsibility principles guide activity see cr principles report explain performance principle use external guidelines frameworks relevant report includes index based gri guidelines aid comparison company reports see gri index wwwgskcom glaxosmithkline corporate responsibility report cr committee members sir christopher gent chairman cr committee sir christopher former chief executive officer vodafone group plc nonexecutive director lehman brothers holdings inc director international advisory board hakluyt co senior adviser bain co sir ian prosser sir ian formerly nonexecutive director smithkline beecham plc chairman chief executive bass plc latterly intercontinental hotel plc chairman world travel tourism council nonexecutive deputy chairman bp plc nonexecutive director sara lee corporation also member cbi president 's committee dr lucy shapiro dr shapiro ludwig professor cancer research department developmental biology director beckman center molecular genetic medicine stanford university school medicine holds phd molecular biology albert einstein college medicine wwwgskcom glaxosmithkline corporate responsibility report management cr principles corporate responsibility statement principles identify key corporate responsibility issues provide guidance employees standards company committed corporate responsibility statement principles mission business improve quality human life enable people feel better live longer focuses needs patients achieve mission products activities enhancing contribution make society sustaining economic performance operating environmentally responsible manner employment practices treat employees respect dignity encourage diversity ensure fair treatment phases employment provide safe healthy working environment support employees perform full potential take responsibility performance reputation business human rights committed upholding un universal declaration human rights oecd guidelines mnes core labour standards set international labour organisation expect standards suppliers contractors business partners working gsks behalf access medicines continue research develop medicines treat diseases developing world find sustainable ways improve access medicines disadvantaged people seek partnerships support activity leadership advocacy establish challenging standards corporate responsibility appropriate complexities specific needs business building external guidelines experience share best practice seek influence others remaining competitive order sustain business community investment make positive contribution communities operate invest health education programmes partnerships aim bring sustainable improvements underserved people developed developing world engagement stakeholders want understand concerns interest corporate wwwgskcom glaxosmithkline corporate responsibility report responsibility issues engage range stakeholders communicate openly addressing cr issues ways aim meet needs different groups allowing us pursue legitimate business goals standards ethical conduct expect employees meet high ethical standards aspects business conducting activities honesty integrity adhering cr principles complying applicable laws regulations research innovation undertaking research innovating may explore apply new technologies constructively engage stakeholders concerns may arise ensure products subject rigorous scientific evaluation testing safety effectiveness quality comply exceed regulations legal standards applicable research development products products customers promote products line high ethical medical scientific standards comply applicable laws regulations caring environment operate environmentally responsible manner systematic management environmental impacts measurement performance setting challenging performance targets improve efficiency activities minimise material energy use waste generated aim find opportunities use renewable materials recycle waste wwwgskcom glaxosmithkline corporate responsibility report summary indicators report wwwgskcom glaxosmithkline corporate responsibility report summary indicators main indicators use track performance range corporate responsibility issues issue medicines developing world supply arrangements preferentially prices antiretrovirals arvs number countries supplied preferentially priced arvs number combivir tablets shipped millions number albendazole tablets donated millions number countries supplied albendazole community investment total community investment expenditure millions value humanitarian product donations including albendazole millions value products donated gsk patient assistance program millions business ethics integrity number employees completing certification code conduct environment number contract manufacturers audited energy consumption million gigajoules water consumption million cubic metres ozone depletion potential metered dose inhalers tonnes cfc equivalent ozone depletion potential production tonnes cfc equivalent ozone depletion potential refrigeration ancillary uses tonnes cfc equivalent volatile organic compound emissions thousand tonnes global warming potential energy sources thousand tonnes co equivalent hazardous waste disposed thousand tonnes health safety lost time injury illness rate cases per hours worked lost time injury illness rate contactors working site cases per hours worked valuing people women management grades ethnic diversity people colour us ethnic diversity ethnic minorities uk research development gsk animal research facilities accredited association assessment accreditation laboratory animal care number trials published gsk clinical trial register wwwgskcom glaxosmithkline corporate responsibility report report report covers corporate responsibility activity performance updates last corporate responsibility report published th march year combined reporting corporate responsibility environment health safety report reporting online first time changes response stakeholder feedback hope make report accessible wider audience data relates calendar year except stated environment data collected pharmaceutical consumer manufacturing sites biologicals manufacturing sites rd sites well distribution centres major office locations smaller office sales locations health safety data covers manufacturing sites rd sites well distribution centres major office locations smaller offices sales locations include data sites operation part year scope data relates worldwide operations except indicated gri index shows elements global reporting initiative guidelines covered report elsewhere website corporate responsibility large subject cover relevant information report background information approach cr available corporate responsibility section website information corporate governance available annual report verification environment health safety sections report externally verified erm environmental resources management web pages verification applies indicated symbol see erms verification statement document wwwgskcom glaxosmithkline corporate responsibility report